

Advancing precision care in pregnancy through an actionable fetal findings list

Authors:

Jennifer L. Cohen¹, Michael Duyzend²⁻⁴, Sophia M. Adelson⁵⁻⁶, Julie Yeo⁷, Mark Fleming⁸, Rebecca Ganetzky⁹⁻¹⁰, Rebecca Hale¹¹, Deborah M. Mitchell¹², Sarah U. Morton¹³⁻¹⁴, Rebecca Reimers¹⁵, Amy Roberts^{14,16}, Alanna Strong^{10, 17-18}, Weizhen Tan^{14, 20}, Jay R. Thiagarajah^{14, 21}, Melissa A. Walker²², Robert C. Green²³⁻²⁵, Nina B. Gold^{7, 14*}

1. Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, North Carolina, USA 2. Department of Pediatrics, Division of Genetics and Genomics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA 3. Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA 4. Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA 5. Brigham and Women's Hospital, Boston, Massachusetts, USA 6. Stanford School of Medicine, Stanford, California, USA 7. Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA 8. Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA 9. Center for Computational Genomic Medicine & Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA 10. Department of Pediatrics, Perelman School of Medicine, Philadelphia, Pennsylvania, USA 11. Department of Pediatrics, Division of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA 12. Division of Pediatric Endocrinology, Massachusetts General Hospital, Boston, Massachusetts, USA 13. Department of Pediatrics, Division of Newborn Medicine, Boston Children's Hospital, Boston, Massachusetts, USA 14. Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA 15. Rady Children's Institute for Genomic Medicine, Rady Children's Hospital Division of Perinatology, Scripps Research Translational Institute, University of California, San Diego, California, USA 16. Department of Cardiology, Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA 17. Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA 18. Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA 20. Division of Pediatric Nephrology, Massachusetts General Hospital for Children, Boston, Massachusetts, USA 21. Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA 22. Department of Neurology, Division of Pediatric Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA 23. Mass General Brigham, Boston, Massachusetts, USA 24. Broad Institute, Cambridge, Massachusetts, USA 25. Ariadne Labs, Boston, Massachusetts, USA 26. Harvard Medical School, Boston, Massachusetts, USA

***Correspondence:** Nina B. Gold, MD. Division of Medical Genetics and Metabolism, Mass

General Hospital for Children, 175 Cambridge Street, Boston, MA 02114

Email: ngold@mgh.harvard.edu, Cell: 617-610-3256

Current word count: 5,188

Summary:

The use of genomic sequencing (GS) for prenatal diagnosis of fetuses with sonographic abnormalities has grown tremendously over the past decade. Fetal GS also offers an opportunity to identify incidental genomic variants that are unrelated to the fetal phenotype, but may be relevant to fetal and newborn health. There are currently no guidelines for reporting incidental findings from fetal GS.

In the United States, GS for adults and children is recommended to include a list of “secondary findings” genes (ACMG SF v3.2) that are associated with disorders for which surveillance or treatment can reduce morbidity and mortality. The genes on ACMG SF v3.2 predominantly cause adult-onset disorders. Importantly, many genetic disorders with fetal and infantile onset are actionable as well.

A proposed solution is to create a “fetal actionable findings list,” which can be offered to pregnant patients undergoing fetal GS or eventually, as a standalone cell-free fetal DNA screening test. In this integrative review, we propose criteria for an actionable fetal findings list, then identify genetic disorders with clinically available or emerging fetal therapies, and those for which clinical detection in the first week of life might lead to improved outcomes. Finally, we synthesize the potential benefits, limitations, and risks of an actionable fetal findings list.

Introduction

The clinical use of genomic sequencing (GS) for prenatal diagnosis of fetuses with sonographic abnormalities has grown tremendously in recent years. The International Society of Prenatal Diagnosis (ISPD) recommends offering fetal GS to patients with pregnancies affected by a major single anomaly, multiple anomalies, or with a history of an undiagnosed fetus or child with a congenital anomaly,¹ likely affecting up to 2-3% of pregnancies.² The diagnostic yield of GS varies by indication, ranging from 2% for isolated increased nuchal translucency to 53% for skeletal abnormalities.³

In the United States, indication-based genome sequencing for children and adults includes the optional analysis of a list of "secondary findings" genes recommended by the American College of Medical Genetics (ACMG) (ACMG SF v3.2).⁴ These genes are predominantly associated with adult-onset cardiac, cancer, and inherited metabolic disorders (IMD). Secondary findings have been identified in at least 1-3% of adults.⁵⁻⁸ Once detected, these disorders can often be managed with medication, dietary changes, or long-term surveillance aimed at improving morbidity and mortality in affected individuals.⁹ The ACMG secondary findings list is recommended both for adults and children undergoing GS, however, professional organizations differ in their recommendations on reporting secondary findings for adult-onset conditions in children. While the recommendations of organizations such as Genomics England¹⁰ generally align with ACMG, the European Society of Human Genetics and others argue that it is premature to screen for later-onset conditions in children.¹¹

The ACMG SF v3.2 recommendations do not apply to fetuses, and guidance regarding the reporting of incidental findings from fetal GS remains unclear.¹² An ACMG Points to Consider

document states that, “prenatal exome sequencing analysis could be limited to the reporting of variants in genes associated with the ultrasound findings,” while also recommending that “highly penetrant pathogenic variants detected in genes unrelated to the fetal phenotype, but known to cause moderate to severe childhood onset disorders, are recommended to be reported.”¹³ The ISPD suggests that secondary findings analyzed in fetal GS might include “moderate to severe childhood conditions,” but does not provide specific guidance on which genes to include.¹ Reporting practices vary across clinical labs, and pregnant patients are not routinely offered a choice regarding the type of genomic findings they receive.

Of note, many pregnancies affected by actionable monogenic conditions show no sonographic abnormalities, or the abnormalities are too subtle to detect with current imaging technology.^{14,15} Recent studies have demonstrated that 0.6-2.7% of sonographically normal fetuses harbor pathogenic or likely pathogenic variants (PLPV) expected to cause genetic disease¹⁶⁻¹⁹ and 1.85% to 9.4% of infants have PLPV associated with a monogenic childhood-onset disorder,^{20,21} including IMD, cardiomyopathies, and syndromic intellectual disability disorders.

Over 700 genetic disorders are now treatable with dietary changes, medication, hematopoietic stem cell transplantation, solid organ transplantation, or gene therapies.²² The number of *in utero* therapies for genetic disorders is rapidly expanding,²³ supported by clinical trials, case reports, and animal model studies. Many of these disorders do not present with ultrasound findings, meaning that the benefits of prenatal therapies can only be realized by patients with known family history or carrier status.²⁴ However, most countries lack a uniform approach to carrier screening²⁵ and the genes included in these panels vary widely, with none addressing *de novo* disorders in the fetus.^{26,27}

Shortly after birth, newborn screening (NBS) identifies many severe, treatable genetic disorders in infants. However, many of the disorders included in NBS programs can cause morbidity or mortality shortly after birth, before the receipt of results at 5 to 7 days of life.²⁸ Prenatal diagnosis of these disorders may allow for improved care during the perinatal period, including: appropriate labor and delivery planning, mobilization of relevant medical teams, and the acquisition of specialized medical formulas, medications, or other therapeutics needed for immediate intervention.

A prior commentary by Gold, *et al* suggested offering pregnant patients who are undergoing fetal GS the optional analysis of an “actionable fetal findings list.”²⁹ Now that fetal exome sequencing using cell-free fetal DNA (cfDNA) is feasible,^{30–32} this list could also serve as the foundation for a non-invasive cfDNA test available to all pregnant patients. This list is not intended to replace NBS or diagnostic GS for infants, but would enhance reproductive options and management capabilities of conditions not typically identified during pregnancy or the immediate perinatal period.

We used an integrative review approach to propose criteria for an actionable fetal findings list, then identified genetic disorders with clinically available or emerging fetal therapies, and those for which clinical detection in the first week of life might lead to improved outcomes. Finally, we synthesized the potential benefits, limitations, and risks of an actionable fetal findings list.

Methods

Study design

The integrative review includes five stages: problem identification, literature search, data evaluation, data analysis, and presentation.^{33,34} This approach allows for the use of several study designs, with the aim of generating new frameworks or ideas.^{33,34}

Selection criteria for genes associated with actionable fetal disorders

We established selection criteria (Table 1) and created three lists: genetic disorders with available or experimental *in utero* therapies (Table 2) and genetic disorders for which prenatal diagnosis could plausibly improve outcomes in the first week of life (Table 3). Genetic disorders with *in utero* therapies that have been used in animal models have been listed separately, as these may be future candidates for an actionable fetal findings list (Table S1).

Inclusion criteria

Safety and efficacy of treatment

With any fetal therapy, two patients are implicated: the pregnant individual and the fetus.³⁵ Because of this, the risk-benefit ratio of a fetal intervention must be tolerable, and there must also be potential efficacy without inflicting undue risk to either the pregnant person or fetus. For example, certain procedural fetal interventions carry a risk of preterm delivery, premature rupture of membranes, and oligohydramnios,³⁶ while the risks of medication administration to the pregnant patient may vary.³⁷ We defined a safe *in utero* therapy as one which did not result in fetal demise, did not lead to adverse side effects in the neonate or child, and did not cause unexpected adverse events in the mother.

Although some disease-targeted interventions have been successful, others have led to adverse events, and therefore were not included. For instance, intrauterine dexamethasone treatment for congenital adrenal hyperplasia (clinicaltrials.gov NCT02795871, NCT00617292) has extensive literature dating back to the 1980s and 1990s, but more recently was discovered to lead to cognitive impairment in children and was therefore deemed to be potentially harmful.^{38–44} Additionally, reports of significant maternal side effects from the dexamethasone administration present another concern.⁴⁵

Disease efficacy was defined as improved neonatal outcomes when compared to the natural history of the disease.^{46, 47–49} We selected only disorders with treatments that are considered to be safe and potentially effective in human case series or clinical trials. For instance, the benefit of an intervention may be incomplete or inconsistent, such as a case report of maternal biotin administration to a fetus with holocarboxylase synthetase deficiency, in which the authors concluded that although it may have improved fetal growth, the prenatally administered dose was insufficient to prevent the neonatal acidotic crisis this particular patient experienced.⁵⁰

For disorders with treatments that may improve clinical outcomes in the first week of life, the available treatments are broadly considered safe for affected infants. In many cases, a confirmatory non-molecular test, such as a biochemical laboratory test or flow cytometry, can be completed shortly after birth to determine if signs of disease are present. Such tests ensure that the appropriate treatment is applied only to infants who are symptomatic or have orthogonal evidence of disease, which is of particular importance for disorders with incomplete penetrance or variable expressivity.

Clinical severity

We selected only disorders that were associated with critical or chronic childhood illness. Additionally, the majority of the disorders included do not lead to structural anomalies. These disorders would therefore not be detected by sonography, nor would they likely be considered causative of a sonographic abnormality for which GS is ordered.

Exclusion criteria

Gene-disease validity

Gene-disease validity refers to the strength of evidence supporting or refuting a claim that variation in a particular gene causes a corresponding monogenic disorder.⁵¹ All tables predominantly include genes with definitive, strong, or moderate gene-disease validity as annotated in ClinGen.⁵¹ Some genes have not yet been curated by ClinGen. Genes with limited, disputed, or refuted ClinGen validity scores have been excluded.

Search strategy for treatable genetic disorders

A literature review was conducted to develop the lists of disorders that can be treated *in utero*. The authors conducted a review of clinicaltrials.gov (search terms: “fetal therapy”, “genetic” returned 256 results, with 8 relevant studies), ChatGPT⁵² and Microsoft CoPilot⁵³ queries for available prenatal therapies for genetic disease, and a medical librarian-led search in Embase (search terms: “fetal therapy,” “fetal treatment,” “*in utero* therapy,” “*in utero* treatment,” “prenatal therapy,” “prenatal treatment” and limited to randomized controlled trials, clinical trials, case studies, and case reports) that yielded 593 titles and abstracts (Table S2) which were reviewed by two authors (J.L.C. and M.D.) for relevance. The searches were limited to English. These titles and abstracts were reviewed using Covidence.⁵⁴ Articles deemed relevant by one or both

authors were added to the tables and manuscript text if they met inclusion criteria. Full text manuscripts were reviewed on an as-needed basis.

To develop a list of disorders that are treatable in the first week of life, the authors reviewed the disorders on the Recommended Uniform Screening Panel (RUSP)⁵⁵ and a list of 651 genes associated with treatable genetic disorders,⁵⁶ aggregated from various online tools and published reports.^{22,57-61} Using these previously compiled lists, the authors included disorders that could benefit from antenatal detection and early postnatal treatment to improve neonatal outcomes. Additionally, the authors incorporated several disorders based on new evidence since the publication of the prior lists or as deemed appropriate according to the selection criteria.

Authors with expertise in various disease areas constructed each clinical section of this list (cardiac disorders: A.R.; endocrine disorders: D.M.M.; gastrointestinal disorders: A.S., J.R.T.; hematologic disorders: M.D.F.; inborn errors of immunity: R.H.; inherited metabolic disorders: R.G., N.B.G.; neurologic disorders: M.A.W.; renal disorders: W.T.). The list of all genes and disorders were then reviewed by the senior author (N.B.G.) for consistency with the selection criteria.

Genetic disorders with *in utero* fetal therapies

Evidence for fetal diagnosis and fetal therapy

An increasing number of genetic disorders can now be treated in the fetal period through a range of therapeutic methods (Figure 1). The evidence for fetal treatment in humans includes case reports and clinical trial data.⁶²⁻⁶⁵

Clinical trials

Systemically administered enzyme replacement therapy delivered through the umbilical cord vein has advanced to human clinical trials. This route of administration, also used for transfusions in fetal anemia,^{66,67} delivers therapy directly to the fetus and has an acceptable safety profile. Another human clinical trial involves intra-amniotic injection of the protein that is absent in X-linked hypohidrotic ectodermal dysplasia.⁶⁸

Additionally, administering low-toxicity medications to a pregnant patient, either orally or through injections or infusions, can treat fetal genetic disorders by crossing the placenta. For instance, certain IMD can be treated with a nutritional supplement or medication provided to the mother, which then crosses the placenta, and improves enzyme activity or prevents toxic substrate accumulation in the fetus.⁶⁹⁻⁷² Furthermore, promising outcomes have also been observed in more prevalent diseases such as cystic fibrosis, in which modulator therapy administered to pregnant patients can improve outcomes of affected fetuses.⁴⁷⁻⁴⁹ The ongoing exploration of therapeutic delivery to the pregnant patient or direct delivery to the fetus remains a viable path forward.

Case reports

Case reports for disorders such as *TRMU* deficiency and cobalamin C deficiency, in which a safe postnatal medication is trialed prenatally via administration to the pregnant person, provide early evidence from which larger prospective clinical trials can be launched.⁶⁹⁻⁷² For these cases, the risk-benefit profile is favorable due to the low potential for maternal medication side effects. Among the case reports of oral administration of medication to a mother carrying an affected fetus, it is evident that the underlying molecular cause of a symptomatic presentation may help guide specific intervention. In a recent example, a case of fetal bradycardia with

positive maternal autoimmune antibodies was found to be unresponsive to maternal dexamethasone treatment, and genetic testing later revealed a *KCNH2* variant-induced long QT syndrome, demonstrating how molecular diagnosis can guide management by alerting the team that conventional prenatal treatment for a common problem may not be sufficient.⁷³ Relatedly, pathogenic variants in *SCN5A*, which can cause long QT syndrome type 3, can be treated with targeted medications.^{73,74} Additionally, there are times that a genetic diagnosis can lead to management changes such as avoiding the otherwise accepted prenatal therapy; for example, fetal chylothorax in fetuses with *PTPN11*-related Noonan syndrome responded poorly to *in utero* pleurodesis by OK-432.⁷⁵

Disorders that require disease-specific delivery management should be considered for inclusion in an actionable fetal findings list as well. For instance, for fetuses affected by a hemophilia or a factor deficiency, cesarean section could be considered and use of vacuum-assisted delivery or forceps should be avoided to prevent intracranial hemorrhage.⁷⁶

Preclinical research

Ongoing preclinical research in the field of fetal gene therapy explores various delivery routes and vectors across mouse, rat, and canine models.⁶²⁻⁶⁵ These delivery routes include injections that are intrahepatic, intracerebroventricular, intraplacental, intraperitoneal, intravenous, and into the yolk sac.⁶² While the field of *in utero* gene therapy and gene editing continues to hold great promise for a range of disorders, some approaches have been met with limited success, such as hematopoietic stem cell gene therapy in a canine model of MPS I, which was unable to reduce disease burden.⁷⁷

Disorders for which prenatal genomic diagnosis may improve outcomes in the first week of life

Although NBS has prevented morbidity and mortality in infants with a range of IMD and other genetic disorders, several disorders included on the RUSP can cause critical illness in the first week of life before NBS results are typically returned. Additionally, there are a range of other disorders that are not yet included in public health NBS programs which also present with symptoms or have clinical therapies that could be initiated promptly after birth.

Evidence for treatment in the first week of life

Cardiac disorders

The genes that most commonly account for long QT syndrome can cause fatal arrhythmias in fetuses or infants, and have even been implicated in some cases of infant and childhood sudden death.^{78,79} Medical management with beta blockers or the implantation of a cardioverter-defibrillator may be lifesaving. Additional genes associated with long QT syndrome account for a very small proportion (<1%) of diagnoses.⁸⁰

Endocrine disorders

Many neonatal-onset endocrine disorders can cause electrolyte disturbances, hypoglycemia, or salt-wasting crises in the first days of life, which lead to neurologic sequelae and even death.^{81,82} While these symptoms can be partially managed without knowledge of the specific genotype, prenatal detection of these disorders may allow for more proactive clinical care and thereby prevent acute manifestations.⁸³ Additionally, in the example of congenital hyperinsulinism, knowledge of the underlying genotype allows for the appropriate treatment to be expedited, as diazoxide may not be effective in certain genetic subtypes.⁸⁴ Relatedly, the more common forms

of neonatal diabetes (*KCNJ11*, *ABCC8*) typically present after the first week of life, but can be improved by targeted treatment with sulfonylureas.⁸⁵

Gastrointestinal disorders

There are several gastrointestinal disorders for which early identification could improve outcomes in infants. A variety of congenital diarrheas and enteropathies manifest immediately after birth and can be treated with disease-specific fluid and electrolyte therapies in the first few days of life.^{86,87} Importantly, limitation of enteral feeding can lead to life-threatening acid-base instability.⁸⁸ Additionally, accurate identification of these disorders may prevent potentially unnecessary evaluations or surgeries for conditions such as pseudo-obstruction, which show similar imaging findings to certain genetic conditions.⁸⁹ Autosomal recessive hyperlipoproteinemia, type 1D, can present with chylomicronemia shortly after birth, and early intervention can reduce morbidity.⁹⁰

Hematologic disorders

A wide variety of genetic disorders of hematopoiesis as well as plasma proteins, particularly those involved in hemostasis, are amenable to *in utero* or perinatal therapies or management strategies. Nearly all severe fetal anemias, for example, respond to *in utero* transfusion, which can bridge the gap to birth, after which chronic transfusion, hematopoietic stem cell transplantation, or, increasingly, gene therapy can be delivered.^{91–98} The erythroid porphyrias, erythropoietic protoporphyria and congenital erythropoietic porphyria, do not themselves cause severe anemia, but the overproduction of porphyrins results in extreme light sensitivity, warranting the avoidance of neonatal phototherapy.⁹⁹ Disorders of granulocyte or platelet numbers or function generally do not cause disease in pre- or perinatal life, but early identification may lead to prophylactic therapies to avoid bleeding or infectious

complications.^{100–102} Recognition of clotting factor deficiencies may be an indication for cesarean section, prompt initiation of factor replacement, or avoidance of common procedures such as circumcision.^{76,103}

Inborn errors of immunity

NBS for severe combined immunodeficiencies (SCID) has improved morbidity and mortality for infants with the most severe form of immunodeficiency. Nonetheless, neonates with SCID can acquire life-threatening infections, in particular cytomegalovirus (CMV) from breast milk, prior to detection by NBS and confirmatory flow cytometry testing.^{104,105} In addition, false negative NBS results for SCID do occasionally occur.¹⁰⁴ Prenatal detection of fetuses at risk for SCID would allow for improved management both pre and post-natally. Prenatally, families could be referred for initial bone marrow transplant evaluation and HLA typing could be initiated. Families could be referred to specific tertiary centers with providers experienced with treating patients with SCID. In the neonatal period, measures including isolation precautions, immune prophylaxis, and counseling against breastfeeding for mothers positive for CMV could further reduce morbidity and mortality as confirmatory testing is performed. Of note, we did not include genes recently associated with SCID which have limited or not yet curated gene-disease relationship based on the ClinGen SCID-CID expert panel, e.g. *MAN2B2* and *BCL11B*, both of which are associated with congenital anomalies and could be ascertained by indication-based testing.¹⁰⁶

Variable expressivity is a common feature of inborn errors of immunity (IEIs), including SCID and combined immunodeficiencies (CIDs). Many genes are associated with both SCID and CIDs, often due to hypomorphic variants linked to the latter. Due to the critical importance of identifying patients at risk for SCID, we included genes associated with CIDs that can present in the neonatal period with SCID.¹⁰⁷ Because of the heterogeneity of CIDs and marked variable

expressivity, it is challenging to definitively distinguish which CIDs would benefit from diagnosis within the first week of life. Early detection of many IELs including CIDs could decrease morbidity and mortality during infancy, but is beyond the scope of this review.⁵⁶

We included genes associated with agammaglobulinemia, a category of disorders predominantly associated with antibody deficiencies. Although infants with agammaglobulinemia typically present at 3-6 months of age, earlier diagnosis and treatment would likely prevent morbidity and mortality.¹⁰⁵ Several countries are implementing B cell kappa chain receptor excision circles (KRECs) screening in conjunction with SCID NBS. This screening can detect patients at risk for agammaglobulinemia.¹⁰⁵ These programs will provide critical information regarding the utility of neonatal detection which can help inform genes chosen for the actionable fetal findings list.

We also included genes associated with diseases of immune dysregulation, congenital defects of phagocyte number, function, or both, defects in intrinsic and innate immunity and autoinflammatory disorders. We included IELs that can present during the neonatal period and are treatable.^{107,108} We did not include complement deficiencies, as the typical age of onset is usually in childhood, although one neonatal presentation has been reported.^{107,108} This is an area of active investigation, in particular for diseases of immune dysregulation and autoinflammatory disorders.¹⁰⁸ We anticipate that the list of genes associated with fetal and perinatal presentation will rapidly increase as these disorders are further characterized with growing awareness of potential fetal presentation.

Variable expressivity and incomplete penetrance are common features of IELs. In particular, for IELs with genotype-phenotype associations, consideration of both gene and specific variant would be important to consider prior to inclusion in an actionable fetal findings list. Neonatal

orthogonal testing for IELs, in particular flow cytometry, is a powerful additional tool when penetrance is unknown.

Inherited metabolic disorders

Many IMD lead to symptoms in the first days of life, prior to the receipt of NBS results. The detection of at-risk fetuses would allow pregnant patients to prepare for delivery in a clinical center where a specialized biochemical genetics team is present, or allow advanced notice for the birth center to procure the necessary metabolic medications and formulas.

In a recent example, a female fetus with pyruvate dehydrogenase deficiency was diagnosed via exome sequencing in the setting of structural brain malformations.¹⁰⁹ This prenatal diagnosis allowed for interdisciplinary delivery planning among the pregnant patient's obstetric providers and the institution's pediatrics teams, including biochemical genetics specialists, neonatologists, and dieticians with expertise in the ketogenic diet. The infant was placed on a ketogenic diet immediately after birth, and as a possible result, experienced no seizures or lactic acidosis in the neonatal period. This case illustrates the potential opportunity for infants with other IMD requiring specialized diets or medications, such as organic acidemias or urea cycle disorders, to receive appropriate treatment beginning at birth. In some cases, prompt initiation of treatment may prevent the accumulation of toxic intermediates that lead to severe metabolic decompensations, characterized by lethargy, seizures, and even early death. Early treatment of IMD therefore has the potential to improve lifelong health and quality of life for affected individuals.

Of note, one challenge that may arise across these disorders is that specific variants in some genes (such as those associated with the myopathic form of carnitine palmitoyltransferase type II deficiency) are strongly associated with attenuated or late-onset forms of disease, which do

not meet the inclusion criteria for this review. If these genes were adapted for an actionable fetal findings list, further discussion will be needed regarding which PLPV to analyze and report.

Neurologic disorders

The management of infants at risk for many monogenic disorders with neurologic symptoms could be improved by identification prior to birth. In particular, several syndromes causing neonatal seizures are optimally treated with specialized management that differs from the standard of care; prompt initiation of the appropriate anti-seizure medication is more likely to lead to complete seizure control.¹¹⁰ Additionally, for disorders such as the congenital myasthenia syndromes, the effect of acetylcholinesterase therapy depends directly on the genotype, which in some cases can worsen symptoms and lead to critical illness.¹¹¹

One unique entity that meets criteria for inclusion is the mtDNA variant m.1555A>G, a risk allele for aminoglycoside-induced deafness. Although this variant is not expected to cause symptoms *a priori*, for infants who undergo preventive treatment of sepsis, commonly-used aminoglycoside antibiotics may put them at risk for hearing loss. Instead, targeted pharmacologic treatment for these infants might lead to the use of a different antibiotic.¹¹²

Renal disorders

Infants at risk for two renal disorders, cystinosis and primary oxaluria, would particularly benefit from treatment in the first week of life to preserve renal function. Cystinosis leads to cystine accumulation in various tissues, including the kidney. Although clinical symptoms do not typically occur until approximately 6 months of age, glomerular damage accumulates from birth. Early treatment with cystine-depleting agents such as cysteamine immediately after birth can slow this damage.^{113,114} Primary oxaluria, which presents in the first months of life in 10% of

affected individuals, results in oxalate accumulation, causing nephrocalcinosis, nephrolithiasis, and progressive kidney damage.¹¹⁵

Discussion

Fetal GS is poised to play an increasingly significant role in prenatal diagnosis. The ISPD recommends offering GS to all pregnant patients whose fetuses have structural abnormalities,¹ which would encompass up to 2-3% of pregnancies.² Currently, no established guidelines regarding which monogenic variants to report in fetal GS exist and the role of secondary findings remains unclear. Importantly, parents have demonstrated interest in using GS to diagnose disorders with available experimental *in utero* therapies. In surveys of parents with children affected by mucopolysaccharidoses, for example, the majority of parents had a favorable attitude toward phase 1 clinical trials for fetal therapy.¹¹⁶ Similarly, survey results from families affected by spinal muscular atrophy and sickle cell disease overwhelmingly supported prenatal diagnosis, and the majority expressed an interest in fetal therapy.^{117,118} Identifying treatable monogenic disorders during the fetal period could therefore enhance patients' care options and autonomy during pregnancy, as well as improve the neonatal and lifelong health of affected infants.

In this integrative review, we compiled a list of 295 genes associated with disorders for which therapeutic intervention—either in the fetus (53 genes) or in the first week of life (267 genes, including 25 genes that appear on both lists)—could improve health outcomes. At present, we suggest that all disorders for which there have been successful treatments reported in individual human cases, disorders with fetal treatments that are currently in clinical trials, and all disorders for which treatment in the first week of life may improve outcomes should be considered for an actionable fetal findings list. This list could be offered to pregnant patients undergoing diagnostic

fetal GS, or as exome sequencing becomes feasible on cfDNA, as a standalone non-invasive screening tool.^{30,119} Of note, however, the list in this review is not comprehensive nor consensus-based and will require updates as new research and therapies emerge.

Although GS allows for querying the entire genome, and any disease-associated genomic finding could be considered actionable in the perinatal period, presenting the option to assess a list of actionable fetal disorders is an important step toward enhancing the autonomy of pregnant patients. In the future, pregnant patients could be offered the option for GS to focus on variants associated with sonographic findings, or to also include additional actionable findings, or analysis of the whole genome. If whole genome analysis were pursued, these lists of disorders could also be used to guide discussions on potential treatment opportunities, which would provide patients with a more comprehensive range of care options. Furthermore, reporting all PLPV associated with childhood-onset disorders may be premature and pose challenges to patient counseling, as the penetrance and expressivity of many variants are not yet well-understood.¹²⁰

Although the treatable disorders listed in this review are all relatively well-characterized in the medical literature, other challenges remain in establishing the clinical utility of an actionable fetal findings list. The penetrance of many of these disorders is unknown and the paucity of diagnostic imaging signs or non-molecular confirmatory testing available in fetuses limits diagnostic certainty.^{121,122} Fetal GS is complicated by incomplete phenotyping due to ultrasound limitations¹⁴ and many disorders may have no discernable prenatal phenotype to substantiate the diagnosis.^{121,122} Efforts are underway to expand entries in the Human Phenotype Ontology related to prenatal presentations; however, this does not address incomplete phenotyping related to technological limitations.¹²² While tests such as fetal enzyme activity using placental¹²³ or umbilical cord blood samples are possible, interpreting results is difficult without established

fetal norms.¹²⁴ After birth, genetic diagnoses can be confirmed by non-genetic findings, but during the fetal period, treatment decisions may rely solely on genetic information.

Implementation of a fetal actionable findings list may also be complicated by barriers to care in resource-limited settings and by psychosocial ramifications. Access to fetal GS is inequitable¹²⁵ and the additional analysis of treatable disease genes could potentially widen health disparities. Reporting only PLPV, as has been recommended by the ACMG, may lead to inequities for reproductive couples of non-European ancestry in whom variants of uncertain significance are more common.¹²⁶ When a positive finding is identified, it may be infeasible for some individuals to receive care at a clinical center where the appropriate treatment is available.¹²⁷ Pregnant patients offered GS in the setting of a fetal anomaly might face an overwhelming amount of information if offered multiple secondary or actionable findings lists.^{128–131} As the clinical use of fetal GS expands, the ethical, legal, and social ramifications of this technology will continue to be a field of active research.

The use of trio GS as a tool to investigate conditions affecting the pregnant patient is also an important new direction for investigation. Given that fetal GS typically includes a sample from the pregnant patient and that the maternal genome is also assessed in cfDNA sequencing, additional genetic disorders that affect fetal or maternal health, or lead to pregnancy complications, could also be considered for inclusion. For example, the pregnant patient's sample could reveal disorders that are teratogenic to the fetus, such as maternal phenylketonuria¹³² or thrombotic thrombocytopenic purpura.¹³³ Additionally, analysis of this sample could identify a risk for disorders that may present in the breastfeeding infant, such as transient neonatal zinc deficiency or acrodermatitis enteropathica,¹³⁴ which can be prevented by supplementation of the deficient nutrient. Furthermore, identifying genetic conditions that affect the health of the pregnant or the postpartum patient, such as ornithine transcarbamylase

deficiency, vascular Ehlers-Danlos syndrome, or cardiomyopathies, could prevent deadly complications such as hyperammonemia or uterine rupture.¹³⁵ Lastly, detecting fetal conditions like fatty acid oxidation disorders, may also inform prenatal care, as they can cause secondary effects in the pregnant patient.¹³⁶

As access to fetal GS grows and the capabilities of cfDNA sequencing advance, the field of prenatal genetic diagnosis will continue to expand. The implementation of an actionable fetal findings list has the potential to enhance the autonomy of pregnant patients and improve the health of infants with rare diseases. There is evidence to suggest that a large number of genes are associated with conditions that are treatable *in utero* or the immediate perinatal period. In time, our understanding of variant curation and prenatal phenotypes will grow, which will improve post-test counseling for pregnant patients with PLPVs found on fetal GS. Although challenges remain regarding the equitable implementation of fetal GS, an actionable fetal findings list could currently be offered to individuals who are undergoing this test, and eventually may form the basis of a non-invasive screening tool performed on cfDNA that could be offered to all pregnant patients.

Declaration of interests: Jennifer Cohen receives compensation for advising at Bayer HealthCare Pharmaceuticals and serves as an advisor on a Sanofi Advisory Board. Michael Duyzend has received a speaking honorarium from Illumina, Inc. Mark Fleming has received compensation for advising the following companies: Vertex Pharmaceuticals, Affymetrix Pharmaceuticals, and Evolve Immune Pharmaceuticals. He also serves on scientific advisory boards for Disc Medicine and Minerva Biotechnologies. Rebecca Ganetzky is a paid consultant for Nurture Genomics & Minovia Therapeutics. Deborah Mitchell receives compensation for advising the following companies: Amolyt, Ascendis. Weizhen Tan serves as a paid consultant for Amgen Pharmaceuticals and participates on an Advisory Board for cystinosis. Melissa Walker is an author on pending patent application U.S. Provisional Patent Application, 63/034,740 "Methods of Detecting Mitochondrial Diseases". Robert Green has received compensation for advising the following companies: Allelica, Atria, Fabric and Juniper Genomics; and is a co-founder of Genome Medical and Nurture Genomics. Nina Gold has received an honorarium from Ambry Genetics.

Acknowledgements: The authors would like to thank Leila Ledbetter for conducting the Embase search on prenatal therapies and Eric Monson for his assistance with Figure 1.

Data and code availability: This study did not generate any datasets or code.

Declaration of generative AI and AI-assisted technologies in the writing process

During the preparation of this work the author(s) used Open AI ChatGPT and Microsoft CoPilot in order to generate ideas about disorders with fetal therapies and clarify grammar and syntax of some sentences. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

References

1. Van den Veyver, I.B., Chandler, N., Wilkins-Haug, L.E., Wapner, R.J., Chitty, L.S., and ISPD Board of Directors (2022). International Society for Prenatal Diagnosis Updated Position Statement on the use of genome-wide sequencing for prenatal diagnosis. *Prenat. Diagn.* *42*, 796–803.
2. Boyd, P.A., Rounding, C., Chamberlain, P., Wellesley, D., and Kurinczuk, J.J. (2012). The evolution of prenatal screening and diagnosis and its impact on an unselected population over an 18-year period. *BJOG* *119*, 1131–1140.
3. Mellis, R., Oprych, K., Scotchman, E., Hill, M., and Chitty, L.S. (2022). Diagnostic yield of exome sequencing for prenatal diagnosis of fetal structural anomalies: A systematic review and meta-analysis. *Prenat. Diagn.* *42*, 662–685.
4. Miller, D.T., Lee, K., Abul-Husn, N.S., Amendola, L.M., Brothers, K., Chung, W.K., Gollob, M.H., Gordon, A.S., Harrison, S.M., Hershberger, R.E., et al. (2023). ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet. Med.* *25*, 100866.
5. Natarajan, P., Gold, N.B., Bick, A.G., McLaughlin, H., Kraft, P., Rehm, H.L., Peloso, G.M., Wilson, J.G., Correa, A., Seidman, J.G., et al. (2016). Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. *Sci. Transl. Med.* *8*, 364ra151.
6. Kim, J., Luo, W., Wang, M., Wegman-Ostrosky, T., Frone, M.N., Johnston, J.J., Nickerson, M.L., Rotunno, M., Li, S.A., Achatz, M.I., et al. (2018). Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. *Genome Med.* *10*, 99.
7. Hart, M.R., Biesecker, B.B., Blout, C.L., Christensen, K.D., Amendola, L.M., Bergstrom, K.L., Biswas, S., Bowling, K.M., Brothers, K.B., Conlin, L.K., et al. (2019). Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. *Genet. Med.* *21*, 1100–1110.
8. eMERGE Clinical Annotation Working Group (2020). Frequency of genomic secondary findings among 21,915 eMERGE network participants. *Genet. Med.* *22*, 1470–1477.
9. Miller, D.T., Lee, K., Chung, W.K., Gordon, A.S., Herman, G.E., Klein, T.E., Stewart, D.R., Amendola, L.M., Adelman, K., Bale, S.J., et al. (2021). ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet. Med.* *23*, 1381–1390.
10. Nolan, J., Buchanan, J., Taylor, J., Almeida, J., Bedenham, T., Blair, E., Broadgate, S., Butler, S., Cazeaux, A., Craft, J., et al. (2024). Secondary (additional) findings from the 100,000 Genomes Project: Disease manifestation, health care outcomes, and costs of disclosure. *Genet. Med.* *26*, 101051.
11. de Wert, G., Dondorp, W., Clarke, A., Dequeker, E.M.C., Cordier, C., Deans, Z., van El, C.G., Fellmann, F., Hastings, R., Hentze, S., et al. (2021). Opportunistic genomic screening.

Recommendations of the European Society of Human Genetics. *Eur. J. Hum. Genet.* **29**, 365–377.

12. Green, R.C., Berg, J.S., Grody, W.W., Kalia, S.S., Korf, B.R., Martin, C.L., McGuire, A.L., Nussbaum, R.L., O’Daniel, J.M., Ormond, K.E., et al. (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet. Med.* **15**, 565–574.

13. Monaghan, K.G., Leach, N.T., Pekarek, D., Prasad, P., Rose, N.C., and ACMG Professional Practice and Guidelines Committee (2020). The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG). *Genet. Med.* **22**, 675–680.

14. Gray, K.J., Wilkins-Haug, L.E., Herrig, N.J., and Vora, N.L. (2019). Fetal phenotypes emerge as genetic technologies become robust. *Prenat. Diagn.* **39**,

15. Zhang-Rutledge, K., Owen, M., Sweeney, N.M., Dimmock, D., Kingsmore, S.F., and Laurent, L.C. (2022). Retrospective identification of prenatal fetal anomalies associated with diagnostic neonatal genomic sequencing results. *Prenat. Diagn.* **42**,

16. Levy, M., Lifshitz, S., Goldenberg-Fumanov, M., Bazak, L., Goldstein, R.J., Hamiel, U., Berger, R., Lipitz, S., Maya, I., and Shohat, M. (2024). Exome sequencing in every pregnancy? Results of trio exome sequencing in structurally normal fetuses. *Prenat. Diagn.*

17. Daum, H., Harel, T., Millo, T., Eilat, A., Fahham, D., Gershon-Naamat, S., Basal, A., Rosenbluh, C., Yanai, N., Porat, S., et al. (2023). Exome sequencing for structurally normal fetuses-yields and ethical issues. *Eur. J. Hum. Genet.* **31**, 164–168.

18. Achiron, R., Kassif, E., Shohat, M., and Kivilevitch, Z. (2022). Pathologic whole exome sequencing analysis in fetuses with minor sonographic abnormal findings and normal chromosomal microarray analysis: case series. *J. Matern. Fetal. Neonatal Med.* **35**, 9730–9735.

19. Vaknin, N., Azoulay, N., Tsur, E., Tripolszki, K., Urzi, A., Rolfs, A., Bauer, P., Achiron, R., Lipitz, S., Goldberg, Y., et al. (2022). High rate of abnormal findings in Prenatal Exome Trio in low risk pregnancies and apparently normal fetuses. *Prenat. Diagn.* **42**, 725–735.

20. Ceyhan-Birsoy, O., Murry, J.B., Machini, K., Lebo, M.S., Yu, T.W., Fayer, S., Genetti, C.A., Schwartz, T.S., Agrawal, P.B., Parad, R.B., et al. (2019). Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project. *Am. J. Hum. Genet.* **104**, 76–93.

21. Dangouloff, T., Hovhannesyan, K., Piazzon, F., Mashhadizadeh, D., Helou, L., Palmeira, L., Boemer, F., and Servais, L. (2023). O10 Universal genomic newborn screening for early, treatable, and severe conditions- including 33 genes of NMD: Baby Detect. *Neuromuscul. Disord.* **33**, S130–S131.

22. Bick, D., Bick, S.L., Dimmock, D.P., Fowler, T.A., Caulfield, M.J., and Scott, R.H. (2021). An online compendium of treatable genetic disorders. *Am. J. Med. Genet. C Semin. Med. Genet.* **187**, 48–54.

23. Sparks, T.N. (2021). The Current State and Future of Fetal Therapies. *Clin. Obstet. Gynecol.* *64*, 926–932.
24. Allen, S.K., Chandler, N.J., Kinning, E., Harrison, V., Brothwell, S.L.C., Vijay, S., Castleman, J., and Cilliers, D. (2024). Diagnosis of inborn errors of metabolism through prenatal exome sequencing with targeted analysis for fetal structural anomalies. *Prenat. Diagn.* *44*, 432–442.
25. Archibald, A.D., McClaren, B.J., Caruana, J., Tutty, E., King, E.A., Halliday, J.L., Best, S., Kanga-Parabia, A., Bennetts, B.H., Cliffe, C.C., et al. (2022). The Australian Reproductive Genetic Carrier Screening Project (Mackenzie’s Mission): Design and Implementation. *J Pers Med* *12*,.
26. Stevens, B., Krstic, N., Jones, M., Murphy, L., and Hoskovec, J. (2017). Finding Middle Ground in Constructing a Clinically Useful Expanded Carrier Screening Panel. *Obstet. Gynecol.* *130*, 279–284.
27. Johansen Taber, K., Ben-Shachar, R., Torres, R., Arjunan, A., Muzzey, D., Kaseniit, K.E., Goldberg, J., and Brown, H. (2022). A guidelines-consistent carrier screening panel that supports equity across diverse populations. *Genet. Med.* *24*, 201–213.
28. Newborn Screening Process.
29. Gold, N.B., Nadel, A., and Green, R.C. (2024). Ready or not, genomic screening of fetuses is already here. *Genet. Med.* *26*, 101008.
30. Brand, H., Whelan, C.W., Duyzend, M., Lemanski, J., Salani, M., Hao, S.P., Wong, I., Valkanas, E., Cusick, C., Genetti, C., et al. (2023). High-Resolution and Noninvasive Fetal Exome Screening. *N. Engl. J. Med.* *389*, 2014–2016.
31. Kitzman, J.O., Snyder, M.W., Ventura, M., Lewis, A.P., Qiu, R., Simmons, L.E., Gammill, H.S., Rubens, C.E., Santillan, D.A., Murray, J.C., et al. (2012). Noninvasive whole-genome sequencing of a human fetus. *Sci. Transl. Med.* *4*, 137ra76.
32. Fan, H.C., Gu, W., Wang, J., Blumenfeld, Y.J., El-Sayed, Y.Y., and Quake, S.R. (2012). Non-invasive prenatal measurement of the fetal genome. *Nature* *487*, 320–324.
33. Torraco, R.J. (2005). Writing Integrative Literature Reviews: Guidelines and Examples. *Human Resource Development Review* *4*, 356–367.
34. Hopia, H., Latvala, E., and Liimatainen, L. (2016). Reviewing the methodology of an integrative review. *Scand. J. Caring Sci.* *30*, 662–669.
35. Vaughn, A., Reynolds, R., Zenge, J., and Marwan, A.I. (2020). Fetal surgery and neonatal ICU admissions. *Curr. Opin. Pediatr.* *32*, 619–624.
36. Molina-Giraldo, S., Zapata Salcedo, R., Rojas Arias, J.L., Acuña Osorio, E., Pinto Quiñones, M.L., Restrepo, H.F., and Cruz-Martinez, R. (2021). Open surgery for in utero repair of spina bifida: Microneurosurgery versus standard technique - A systematic review. *Prenat. Diagn.* *41*, 1615–1623.

37. Hendriks, S., Grady, C., Wasserman, D., Wendler, D., Bianchi, D.W., and Berkman, B.E. (2022). A New Ethical Framework for Assessing the Unique Challenges of Fetal Therapy Trials. *Am. J. Bioeth.* 22, 45–61.
38. McCann-Crosby, B., Placencia, F.X., Adeyemi-Fowode, O., Dietrich, J., Franciskovich, R., Gunn, S., Axelrad, M., Tu, D., Mann, D., Karaviti, L., et al. (2018). Challenges in Prenatal Treatment with Dexamethasone. *Pediatr. Endocrinol. Rev.* 16, 186–193.
39. David, M., and Forest, M.G. (1984). Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. *J. Pediatr.* 105, 799–803.
40. M. I. New (2001). EXTENSIVE PERSONAL EXPERIENCE: Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. *J. Clin. Endocrinol. Metab.* 86, 5651–5657.
41. Pang, S.Y., Pollack, M.S., Marshall, R.N., and Immken, L. (1990). Prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *N. Engl. J. Med.* 322, 111–115.
42. Haan, E.A., Penfold, J.L., Richards, R.I., Serjeantson, S.W., Rollond, A.K., Norman, R., and Antonis, P. (1992). Prenatal diagnosis and successful intrauterine treatment of a female fetus with 21-hydroxylase deficiency. *Med. J. Aust.* 156, 132–135.
43. Cerase, B.I., Newfield, R.S., Pascoe, L., Curnow, K.M., Nimkarn, S., Roe, T.F., New, M.I., and Wilson, R.C. (1999). Prenatal diagnosis and treatment of 11beta-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. *J. Clin. Endocrinol. Metab.* 84, 3129–3134.
44. Speiser, P.W., Arlt, W., Auchus, R.J., Baskin, L.S., Conway, G.S., Merke, D.P., Meyer-Bahlburg, H.F.L., Miller, W.L., Murad, M.H., Oberfield, S.E., et al. (2018). Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clinical practice guideline. *J. Clin. Endocrinol. Metab.* 103, 4043–4088.
45. Pang, S., Clark, A.T., Freeman, L.C., Dolan, L.M., Immken, L., Mueller, O.T., Stiff, D., and Shulman, D.I. (1992). Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. *J. Clin. Endocrinol. Metab.* 75, 249–253.
46. Cohen, J.L., Chakraborty, P., Fung-Kee-Fung, K., Schwab, M.E., Bali, D., Young, S.P., Gelb, M.H., Khaledi, H., DiBattista, A., Smallshaw, S., et al. (2022). In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe’s Disease. *N. Engl. J. Med.* 387, 2150–2158.
47. Blumenfeld, Y.J., Hintz, S.R., Aziz, N., Barth, R.A., Spano, J.M., El-Sayed, Y.Y., and Milla, C. (2023). Treatment of Fetal Cystic Fibrosis With Cystic Fibrosis Transmembrane Conductance Regulator Modulation Therapy. *Ann. Intern. Med.* 176, 1015–1016.
48. Fortner, C.N., Seguin, J.M., and Kay, D.M. (2021). Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. *J. Cyst. Fibros.* 20, 835–836.
49. Szentpetery, S., Foil, K., Hendrix, S., Gray, S., Mingora, C., Head, B., Johnson, D., and Flume, P.A. (2022). A case report of CFTR modulator administration via carrier mother to treat

meconium ileus in a F508del homozygous fetus. *J. Cyst. Fibros.* 21, 721–724.

50. Yokoi, K., Ito, T., Maeda, Y., Nakajima, Y., Kurono, Y., Sugiyama, N., and Togari, H. (2009). A case of holocarboxylase synthetase deficiency with insufficient response to prenatal biotin therapy. *Brain Dev.* 31, 775–778.

51. Rehm, H.L., Berg, J.S., Brooks, L.D., Bustamante, C.D., Evans, J.P., Landrum, M.J., Ledbetter, D.H., Maglott, D.R., Martin, C.L., Nussbaum, R.L., et al. (2015). ClinGen—the Clinical Genome Resource. *N. Engl. J. Med.* 372, 2235–2242.

52. OpenAI. (2024). ChatGPT (Accessed: May 2024–September 2024) [GPT-4o model]. <https://chat.openai.com/chat>.

53. Microsoft. (2024). Microsoft Copilot (Accessed: May 2024–September 2024). <https://copilot.microsoft.com>.

54. (2020). Covidence - Better systematic review management.

55. (2023). Recommended uniform screening panel.

56. Gold, N.B., Adelson, S.M., Shah, N., Williams, S., Bick, S.L., Zoltick, E.S., Gold, J.I., Strong, A., Ganetzky, R., Roberts, A.E., et al. (2023). Perspectives of rare disease experts on newborn genome sequencing. *JAMA Netw. Open* 6, e2312231.

57. Lee, J.J.Y., Wasserman, W.W., Hoffmann, G.F., van Karnebeek, C.D.M., and Blau, N. (2018). Knowledge base and mini-expert platform for the diagnosis of inborn errors of metabolism. *Genet. Med.* 20, 151–158.

58. Hoytema van Konijnenburg, E.M.M., Wortmann, S.B., Koelewijn, M.J., Tseng, L.A., Houben, R., Stöckler-Ipsiroglu, S., Ferreira, C.R., and van Karnebeek, C.D.M. (2021). Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app. *Orphanet J. Rare Dis.* 16, 170.

59. DeCristo, D.M., Milko, L.V., O'Daniel, J.M., Foreman, A.K.M., Mollison, L.F., Powell, B.C., Powell, C.M., and Berg, J.S. (2021). Actionability of commercial laboratory sequencing panels for newborn screening and the importance of transparency for parental decision-making. *Genome Med.* 13, 50.

60. Gold, N.B., Harrison, S.M., Rowe, J.H., Gold, J., Furutani, E., Biffi, A., Duncan, C.N., Shimamura, A., Lehmann, L.E., and Green, R.C. (2022). Low frequency of treatable pediatric disease alleles in gnomAD: An opportunity for future genomic screening of newborns. *Human Genetics and Genomics Advances* 3, 100059.

61. Yeh, J.M., Stout, N.K., Chaudhry, A., Christensen, K.D., Gooch, M., McMahon, P.M., O'Brien, G., Rehman, N., Blout Zawatsky, C.L., Green, R.C., et al. (2021). Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. *Genet. Med.* 23, 1366–1371.

62. Waddington, S.N., Peranteau, W.H., Rahim, A.A., Boyle, A.K., Kurian, M.A., Gissen, P., Chan, J.K.Y., and David, A.L. (2024). Fetal gene therapy. *J. Inherit. Metab. Dis.* 47, 192–210.

63. Hartman, H.A., Rossidis, A.C., and Peranteau, W.H. (2018). In Utero Gene Therapy and Genome Editing. *Current Stem Cell Reports* 4, 52–60.
64. Mattar, C.N.Z., Chan, J.K.Y., and Choolani, M. (2023). Gene modification therapies for hereditary diseases in the fetus. *Prenat. Diagn.* 43, 674–686.
65. Kong, C., Yin, G., Wang, X., and Sun, Y. (2024). In Utero Gene Therapy and its Application in Genetic Hearing Loss. *Adv Biol (Weinh)* e2400193.
66. Oepkes, D., and van Scheltema P, A. (2007). Intrauterine fetal transfusions in the management of fetal anemia and fetal thrombocytopenia. *Semin. Fetal Neonatal Med.* 12,.
67. Gallot, D., Boiret, N., Vanlieferinghen, P., Laurichesse, H., Micorek, J.C., Berger, M., and Lemery, D. (2004). The peritoneal route as a safe pathway for early in utero therapies: illustration by a 12-year follow-up after conservative management of severe Rhesus allo-immunization. *Fetal Diagn. Ther.* 19, 170–173.
68. Schneider, H., Faschingbauer, F., Schuepbach-Mallepell, S., Körber, I., Wohlfart, S., Dick, A., Wahlbuhl, M., Kowalczyk-Quintas, C., Vigolo, M., Kirby, N., et al. (2018). Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia. *N. Engl. J. Med.* 378, 1604–1610.
69. Murali, C.N., Soler-Alfonso, C., Loomes, K.M., Shah, A.A., Monteil, D., Padilla, C.D., Scaglia, F., and Ganetzky, R. (2021). TRMU deficiency: A broad clinical spectrum responsive to cysteine supplementation. *Mol. Genet. Metab.* 132, 146–153.
70. Trefz, F.K., Scheible, D., Frauendienst-Egger, G., Huemer, M., Suomala, T., Fowler, B., Haas, D., and Baumgartner, M.R. (2016). Successful intrauterine treatment of a patient with cobalamin C defect. *Mol Genet Metab Rep* 6, 55–59.
71. Huemer, M., Simma, B., Fowler, B., Suormala, T., Bodamer, O.A., and Sass, J.O. (2005). Prenatal and postnatal treatment in cobalamin C defect. *J. Pediatr.* 147, 469–472.
72. Brunel-Guitton, C., Costa, T., Mitchell, G.A., and Lambert, M. (2010). Treatment of cobalamin C (cblC) deficiency during pregnancy. *J. Inherit. Metab. Dis.* 33 *Suppl* 3, S409–S412.
73. Wei, L., Wu, J., Xie, P., Liu, X., Hua, Y., Zhou, K., Wang, C., and Li, Y. (2023). A rare case with fetal autoimmune heart block and KNCH2 variant–induced long QT syndrome: a controversial opinion on prenatal management strategy. *BMC Cardiovasc. Disord.* 23, 1–9.
74. Anuwutnavin, S., Wanitpongpan, P., Chungsomprasong, P., Soongswang, J., Srisantiroj, N., and Wataganara, T. (2013). Fetal long QT syndrome manifested as atrioventricular block and ventricular tachycardia: a case report and a review of the literature. *Pediatr. Cardiol.* 34, 1955–1962.
75. Chen, C.H., Chen, T.H., Kuo, S.J., Chen, C.P., Lee, D.J., Ke, Y.Y., Yeh, K.T., Ma, G.C., Liu, C.S., Shih, J.C., et al. (2009). Genetic evaluation and management of fetal chylothorax: review and insights from a case of Noonan syndrome. *Lymphology* 42, 134–138.
76. Kulkarni, R., Soucie, J.M., Lusher, J., Presley, R., Shapiro, A., Gill, J., Manco-Johnson, M., Koerper, M., Mathew, P., Abshire, T., et al. (2009). Sites of initial bleeding episodes, mode of

delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. *Haemophilia* 15, 1281–1290.

77. Lutzko, C., Omori, F., Abrams-Ogg, A.C., Shull, R., Li, L., Lau, K., Ruedy, C., Nanji, S., Gartley, C., Dobson, H., et al. (1999). Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. *Hum. Gene Ther.* 10, 1521–1532.

78. Liebrechts-Akkerman, G., Liu, F., van Marion, R., Dinjens, W.N.M., and Kayser, M. (2020). Explaining sudden infant death with cardiac arrhythmias: Complete exon sequencing of nine cardiac arrhythmia genes in Dutch SIDS cases highlights new and known DNA variants. *Forensic Sci. Int. Genet.* 46, 102266.

79. Kotta, M.-C., Torchio, M., Bayliss, P., Cohen, M.C., Quarrell, O., Wheeldon, N., Marton, T., Gentilini, D., Crotti, L., Coombs, R.C., et al. (2023). Cardiac genetic investigation of Sudden infant and early childhood death: A study from victims to families. *J. Am. Heart Assoc.* 12, e029100.

80. Groffen, A.J., Bikker, H., and Christiaans, I. (2024). Long QT Syndrome Overview (University of Washington, Seattle).

81. Malpuech, G., Vanlieferinghen, P., Dechelotte, P., Gaulme, J., Labbé, A., and Guiot, F. (1988). Isolated familial adrenocorticotropin deficiency: prenatal diagnosis by maternal plasma estriol assay. *Am. J. Med. Genet.* 29, 125–130.

82. Gerard, R., Sauvestre, C., Barat, P., Harambat, J., Janot, C., Mallet, D., Roucher-Boulez, F., and Allard, L. (2024). Neonatal salt wasting syndrome: Aldosterone synthase deficiency caused by a new splicing variant in CYP11B2. *Arch. Pediatr.* 31, 157–160.

83. Yoon, J.-H., Hwang, S., Kim, J.H., Kim, G.-H., Yoo, H.-W., and Choi, J.-H. (2024). Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency through molecular genetic analysis of the CYP21A2 gene. *Ann. Pediatr. Endocrinol. Metab.* 29, 54–59.

84. Snider, K.E., Becker, S., Boyajian, L., Shyng, S.-L., MacMullen, C., Hughes, N., Ganapathy, K., Bhatti, T., Stanley, C.A., and Ganguly, A. (2013). Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. *J. Clin. Endocrinol. Metab.* 98, E355–E363.

85. Bizzarri, C., Schiaffini, R., and Patera, I.P. (2023). History of neonatal diabetes. In *Neonatal and Early Onset Diabetes Mellitus*, (Cham: Springer International Publishing), pp. 1–7.

86. Fiskerstrand, T., Arshad, N., Haukanes, B.I., Tronstad, R.R., Pham, K.D.-C., Johansson, S., Håvik, B., Tønder, S.L., Levy, S.E., Brackman, D., et al. (2012). Familial diarrhea syndrome caused by an activating GUCY2C mutation. *N. Engl. J. Med.* 366, 1586–1595.

87. National Center for Biotechnology Information (US) (1998). Glucose galactose malabsorption (National Center for Biotechnology Information (US)).

88. Jones, B.J.M. (2023). Acid-base disturbances. In *Intestinal Failure*, (Cham: Springer International Publishing), pp. 377–390.

89. Babcock, S.J., Flores-Marin, D., and Thiagarajah, J.R. (2023). The genetics of monogenic intestinal epithelial disorders. *Hum. Genet.* *142*, 613–654.
90. Buonomo, P.S., Bartuli, A., Rabacchi, C., Bertolini, S., and Calandra, S. (2015). A 3-day-old neonate with severe hypertriglyceridemia from novel mutations of the GPIHBP1 gene. *J. Clin. Lipidol.* *9*, 265–270.
91. Valsky, D.V., Daum, H., and Yagel, S. (2007). Reversal of mirror syndrome after prenatal treatment of Diamond-Blackfan anemia. *Prenat. Diagn.* *27*, 1161–1164.
92. Kreger, E.M., Singer, S.T., Witt, R.G., Sweeters, N., Lianoglou, B., Lal, A., Mackenzie, T.C., and Vichinsky, E. (2016). Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. *Prenat. Diagn.* *36*, 1242–1249.
93. Chmait, R.H., Baskin, J.L., Carson, S., Randolph, L.M., and Hamilton, A. (2015). Treatment of alpha(0)-thalassemia (--(SEA)/--(SEA)) via serial fetal and post-natal transfusions: Can early fetal intervention improve outcomes? *Hematology* *20*, 217–222.
94. Carr, S., Rubin, L., Dixon, D., Star, J., and Dailey, J. (1995). Intrauterine therapy for homozygous α -thalassemia. *Obstetrics & Gynecology* *85*, 876–879.
95. Lugthart, G., Verweij, E.J.T., Hartevelde, C.L., Tan, R.N.G.B., Knapen, M.F.C.M., Slaghekke, F., Haak, M.C., Mohseny, A.B., and Smiers, F.J. (2024). Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha-thalassemia. *Am. J. Hematol.* *99*, 1613–1615.
96. Horvei, P., MacKenzie, T., and Kharbanda, S. (2021). Advances in the management of α -thalassemia major: reasons to be optimistic. *Hematology Am. Soc. Hematol. Educ. Program* *2021*, 592–599.
97. Hayward, A., Ambruso, D., Battaglia, F., Donlon, T., Eddelman, K., Giller, R., Hobbins, J., Hsia, Y.E., Quinones, R., Shpall, E., et al. (1998). Microchimerism and tolerance following intrauterine transplantation and transfusion for alpha-thalassemia-1. *Fetal Diagn. Ther.* *13*, 8–14.
98. Migliaccio, A.R., Migliaccio, G., Di Baldassarre, A., and Eddleman, K. (2002). Circulating hematopoietic progenitor cells in a fetus with alpha thalassemia: comparison with the cells circulating in normal and non-thalassemic anemia fetuses and implications for in utero transplantations. *Bone Marrow Transplant.* *30*, 75–80.
99. Nordmann, Y., Amram, D., Deybach, J.C., Phung, L.N., and Lesbros, D. (1990). Coexistent hereditary coproporphyrin and congenital erythropoietic porphyria (Günther disease). *J. Inher. Metab. Dis.* *13*, 687–691.
100. Goldberg, L.R., Glasser, L., Wu, T., Shimizu, I., Quesenberry, P.J., and Butera, J.N. (2009). Successful Treatment of Acquired Amegakaryocytic Thrombocytopenia with Rituximab: A Case Report. *Blood* *114*, 4223–4223.
101. Voit, R.A., and Sankaran, V.G. (2023). MECOM Deficiency: from Bone Marrow Failure to Impaired B-Cell Development. *J. Clin. Immunol.* *43*, 1052–1066.

102. Toro, C., Morimoto, M., Malicdan, M.C., Adams, D.R., and Introne, W.J. (2023). Chediak-Higashi Syndrome (University of Washington, Seattle).
103. Konkle, B.A., and Fletcher, S.N. (2023). Hemophilia A (University of Washington, Seattle).
104. Puck, J.M. (2019). Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. *Immunol. Rev.* 287,.
105. Currier, R., and Puck, J.M. (2021). SCID newborn screening: What we've learned. *J. Allergy Clin. Immunol.* 147,.
106. Dvorak, C.C., Haddad, E., Heimall, J., Dunn, E., Cowan, M.J., Pai, S.Y., Kapoor, N., Satter, L.F., Buckley, R.H., O'Reilly, R.J., et al. (2023). The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions. *J. Allergy Clin. Immunol.* 151,.
107. O'Connell, A.E. (2019). Primary Immunodeficiency in the NICU. *Neoreviews* 20, e67–e78.
108. Carneiro-Sampaio, M., de Jesus, A.A., Bando, S.Y., and Moreira-Filho, C.A. (2022). Inborn Errors of Immunity With Fetal or Perinatal Clinical Manifestations. *Front Pediatr* 10, 891343.
109. Bowen, A.B., Rapalino, O., Jaimes, C., Ratai, E.-M., Zhong, Y., Thiele, E.A., Kritzer, A., Ganetzky, R.D., Gold, N.B., and Walker, M.A. (2024). Prenatal molecular diagnosis of pyruvate dehydrogenase complex deficiency enables rapid initiation of ketogenic diet. *Am. J. Med. Genet. A* e63825.
110. Striano, P., and Minassian, B.A. (2020). From Genetic Testing to Precision Medicine in Epilepsy. *Neurotherapeutics* 17, 609–615.
111. Abicht, A., Müller, J.S., and Lochmüller, H. (2021). Congenital Myasthenic Syndromes Overview (University of Washington, Seattle).
112. McDermott, J.H., Mahaveer, A., James, R.A., Booth, N., Turner, M., Harvey, K.E., Miele, G., Beaman, G.M., Stoddard, D.C., Tricker, K., et al. (2022). Rapid point-of-care genotyping to avoid aminoglycoside-induced ototoxicity in neonatal intensive care. *JAMA Pediatr.* 176, 486–492.
113. Kleta, R., Bernardini, I., Ueda, M., Varade, W.S., Phornphutkul, C., Krasnewich, D., and Gahl, W.A. (2004). Long-term follow-up of well-treated nephropathic cystinosis patients. *J. Pediatr.* 145, 555–560.
114. Hohenfellner, K., Bergmann, C., Fleige, T., Janzen, N., Burggraf, S., Olgemöller, B., Gahl, W.A., Czibere, L., Froschauer, S., Röschinger, W., et al. (2019). Molecular based newborn screening in Germany: Follow-up for cystinosis. *Mol Genet Metab Rep* 21, 100514.
115. Patwardhan, A., and Higgins, C. (2005). Primary hyperoxaluria type-1: an unprecedented presentation at birth. *Indian Pediatr.* 42, 173–174.
116. Schwab, M.E., Brown, J.E.H., Lianoglou, B., Jin, C., Conroy, P.C., Gallagher, R.C., Harmatz, P., and MacKenzie, T.C. (2022). Fetal therapies and trials for lysosomal storage

diseases: a survey of attitudes of parents and patients. *Orphanet J. Rare Dis.* 17, 25.

117. Schwab, M.E., Shao, S., Zhang, L., Lianoglou, B., Belter, L., Jarecki, J., Schroth, M., Sumner, C.J., and MacKenzie, T. (2022). Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy. *Prenat. Diagn.* 42, 1409–1419.

118. Antiel, R.M., Halpern, S.D., Stevens, E.M., Vrecenak, J.D., Patterson, C.A., Tchume-Johnson, T., Smith-Whitley, K., Peranteau, W.H., Flake, A.W., and Barakat, L.P. (2017). Acceptability of in utero hematopoietic cell transplantation for sickle cell disease. *Med. Decis. Making* 37, 914–921.

119. Miceikaitė, I., Hao, Q., Brasch-Andersen, C., Fagerberg, C.R., Topping, P.M., Kristiansen, B.S., Ousager, L.B., Sperling, L., Ibsen, M.H., Löser, K., et al. (2023). Comprehensive Noninvasive Fetal Screening by Deep Trio-Exome Sequencing. *N. Engl. J. Med.* 389, 2017–2019.

120. Kingdom, R., and Wright, C.F. (2022). Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts. *Front. Genet.* 13, 920390.

121. Zhang, J., Li, J., Saucier, J.B., Feng, Y., Jiang, Y., Sinson, J., McCombs, A.K., Schmitt, E.S., Peacock, S., Chen, S., et al. (2019). Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA. *Nat. Med.* 25, 439–447.

122. Dhombres, F., Morgan, P., Chaudhari, B.P., Filges, I., Sparks, T.N., Lapunzina, P., Roscioli, T., Agarwal, U., Aggarwal, S., Beneteau, C., et al. (2022). Prenatal phenotyping: A community effort to enhance the Human Phenotype Ontology. *Am. J. Med. Genet. C Semin. Med. Genet.* 190, 231–242.

123. Grabowski, G.A., Kruse, J.R., Goldberg, J.D., Chockkalingam, K., Gordon, R.E., Blakemore, K.J., Mahoney, M.J., and Desnick, R.J. (1984). First-trimester prenatal diagnosis of Tay-Sachs disease. *Am. J. Hum. Genet.* 36, 1369–1378.

124. Faivre, L., Cormier-Daire, V., Chrétien, D., Christoph von Kleist-Retzow, J., Amiel, J., Dommergues, M., Saudubray, J.M., Dumez, Y., Rötig, A., Rustin, P., et al. (2000). Determination of enzyme activities for prenatal diagnosis of respiratory chain deficiency. *Prenat. Diagn.* 20, 732–737.

125. Sahin-Hodoglugil, N.N., Lianoglou, B.R., Ackerman, S., Sparks, T.N., and Norton, M.E. (2023). Access to prenatal exome sequencing for fetal malformations: A qualitative landscape analysis in the US. *Prenat. Diagn.* 43, 1394–1405.

126. Caswell-Jin, J.L., Gupta, T., Hall, E., Petrovchich, I.M., Mills, M.A., Kingham, K.E., Koff, R., Chun, N.M., Levonian, P., Lebensohn, A.P., et al. (2018). Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. *Genet. Med.* 20, 234–239.

127. Taylor, M., Khan, S., Stapleton, M., Wang, J., Chen, J., Wynn, R., Yabe, H., Chinen, Y., Boelens, J.J., Mason, R.W., et al. (2019). Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future. *Biol. Blood Marrow Transplant.* 25, e226–e246.

128. Robinson, J.O. (2021). Ask me later: deciding to have clinical exome trio sequencing for my critically ill child. *Genet. Med.* *23*, 1836–1837.
129. Gereis, J., Hetherington, K., Ha, L., Robertson, E.G., Ziegler, D.S., Barlow-Stewart, K., Tucker, K.M., Marron, J.M., and Wakefield, C.E. (2022). Parents' understanding of genome and exome sequencing for pediatric health conditions: a systematic review. *Eur. J. Hum. Genet.* *30*, 1216–1225.
130. Narayanan, S., Blumberg, B., Clayman, M.L., Pan, V., and Wicklund, C. (2018). Exploring the Issues Surrounding Clinical Exome Sequencing in the Prenatal Setting. *J. Genet. Couns.* *27*, 1228–1237.
131. Brown, J.E.H., Zamora, A.N., Outram, S., Sparks, T.N., Lianoglou, B.R., Norstad, M., Sahin Hodoglugil, N.N., Norton, M.E., and Ackerman, S.L. (2022). “Let’s Just Wait Until She’s Born”: Temporal Factors That Shape Decision-Making for Prenatal Genomic Sequencing Amongst Families Underrepresented in Genomic Research. *Front. Genet.* *13*, 882703.
132. Alghamdi, M.A., O’Donnell-Luria, A., Almontashiri, N.A., AlAali, W.Y., Ali, H.H., and Levy, H.L. (2023). Classical phenylketonuria presenting as maternal PKU syndrome in the offspring of an intellectually normal woman. *JIMD Rep.* *64*, 312–316.
133. Ferrari, B., and Peyvandi, F. (2020). How I treat thrombotic thrombocytopenic purpura in pregnancy. *Blood* *136*, 2125–2132.
134. Yang, W.-L., Hsu, C.-K., Chao, S.-C., Huang, C.-Y., and Lee, J.Y.-Y. (2012). Transient zinc deficiency syndrome in a breast-fed infant due to decreased zinc in breast milk (type II hypozincemia of infancy): A case report and review of the literature. *Dermatologica Sinica* *30*, 66–70.
135. Feigenbaum, A., Lamale-Smith, L., and Weinstein, L. (2022). Considerations for prenatal and postpartum management of a female patient with ornithine transcarbamylase deficiency. *Mol Genet Metab Rep* *33*, 100894.
136. Gibson, R.A., Abar, B., Elman, L.N., Walsh, K.M., Hurst, J.H., and Cohen, J.L. (2024). Identifying associations between genetic conditions in offspring and pregnancy health complications. *Reprod. Female Child Health* *3*,.
137. Rucker, M., Fraitas, T.J., Jr, Porvasnik, S.L., Lewis, M.A., Zolotukhin, I., Cloutier, D.A., and Byrne, B.J. (2004). Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. *Development* *131*, 3007–3019.
138. Meertens, L., Zhao, Y., Rosic-Kablar, S., Li, L., Chan, K., Dobson, H., Gartley, C., Lutzko, C., Hopwood, J., Kohn, D., et al. (2002). In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression. *Hum. Gene Ther.* *13*, 1809–1820.
139. Bose, S.K., White, B.M., Kashyap, M.V., Dave, A., De Bie, F.R., Li, H., Singh, K., Menon, P., Wang, T., Teerdhala, S., et al. (2021). In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease. *Nat. Commun.* *12*, 4291.

140. Casal, M.L., and Wolfe, J.H. (1997). Amphotropic and ecotropic retroviral vector viruses transduce midgestational murine fetal liver cells in a dual-chambered cocultivation system. *Gene Ther.* *4*, 39–44.
141. Casal, M.L., and Wolfe, J.H. (2001). In utero transplantation of fetal liver cells in the mucopolysaccharidosis type VII mouse results in low-level chimerism, but overexpression of beta-glucuronidase can delay onset of clinical signs. *Blood* *97*, 1625–1634.
142. Karolewski, B.A., and Wolfe, J.H. (2006). Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. *Mol. Ther.* *14*, 14–24.
143. Shen, J.-S., Meng, X.-L., Maeda, H., Ohashi, T., and Eto, Y. (2004). Widespread gene transduction to the central nervous system by adenovirus in utero: implication for prenatal gene therapy to brain involvement of lysosomal storage disease. *J. Gene Med.* *6*, 1206–1215.
144. Massaro, G., Mattar, C.N.Z., Wong, A.M.S., Sirka, E., Buckley, S.M.K., Herbert, B.R., Karlsson, S., Perocheau, D.P., Burke, D., Heales, S., et al. (2018). Fetal gene therapy for neurodegenerative disease of infants. *Nat. Med.* *24*, 1317–1323.
145. Schneider, H., Hadj-Rabia, S., Faschingbauer, F., Bodemer, C., Grange, D.K., Norton, M.E., Cavalli, R., Tadini, G., Stepan, H., Clarke, A., et al. (2023). Protocol for the phase 2 EDELIFE trial investigating the efficacy and safety of intra-amniotic ER004 administration to male subjects with X-linked hypohidrotic ectodermal dysplasia. *Genes* *14*, 153.
146. Crimmins, S., Vashit, S., Doyle, L., Harman, C., Turan, O., and Turan, S. (2017). A multidisciplinary approach to prenatal treatment of congenital long QT syndrome. *J. Clin. Ultrasound* *45*, 168–170.
147. Chang, I.-K., Shyu, M.-K., Lee, C.-N., Kau, M.-L., Ko, Y.-H., Chow, S.-N., and Hsieh, F.-J. (2002). Prenatal diagnosis and treatment of fetal long QT syndrome: a case report. *Prenat. Diagn.* *22*, 1209–1212.
148. Hofbeck, M., Ulmer, H., Beinder, E., Sieber, E., and Singer, H. (1997). Prenatal findings in patients with prolonged QT interval in the neonatal period. *Heart* *77*, 198–204.
149. Schneider, U., Haueisen, J., Loeff, M., Bondarenko, N., and Schleussner, E. (2005). Prenatal diagnosis of a long QT syndrome by fetal magnetocardiography in an unshielded bedside environment. *Prenat. Diagn.* *25*, 704–708.
150. Simpson, J.M., Maxwell, D., Rosenthal, E., and Gill, H. (2009). Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature. *Ultrasound Obstet. Gynecol.* *34*, 475–480.
151. Grüner, C., Kollert, A., Wildt, L., Dörr, H.G., Beinder, E., and Lang, N. (2001). Intrauterine treatment of fetal goitrous hypothyroidism controlled by determination of thyroid-stimulating hormone in fetal serum. A case report and review of the literature. *Fetal Diagn. Ther.* *16*, 47–51.
152. Refetoff, S., Pappa, T., Williams, M.K., Matheus, M.G., Liao, X.-H., Hansen, K., Nicol, L., Pierce, M., Blasco, P.A., Wiebers Jensen, M., et al. (2021). Prenatal Treatment of Thyroid

Hormone Cell Membrane Transport Defect Caused by MCT8 Gene Mutation. *Thyroid* 31, 713–720.

153. Kao, Y.-T., Yen, C.-C., Fan, H.-C., Chen, J.-K., Chen, M.-S., Lan, Y.-W., Yang, S.-H., and Chen, C.-M. (2023). In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment. *Int. J. Mol. Sci.* 24,.

154. Tamblyn, J.A., Norton, A., Spurgeon, L., Donovan, V., Bedford Russell, A., Bonnici, J., Perkins, K., Vyas, P., Roberts, I., and Kilby, M.D. (2016). Prenatal therapy in transient abnormal myelopoiesis: a systematic review. *Arch. Dis. Child. Fetal Neonatal Ed.* 101, F67–F71.

155. Flake Alan W., Roncarolo Maria-Grazia, Puck Jennifer M., Almeida-Porada Graza, Evans Mark I., Johnson Mark P., Abella Estaban M., Harrison Duane D., and Zanjani Esmail D. Treatment of X-Linked Severe Combined Immunodeficiency by in Utero Transplantation of Paternal Bone Marrow. *N. Engl. J. Med.* 335, 1806–1810.

156. Magnani, A., Jouannic, J.-M., Rosain, J., Gabrion, A., Touzot, F., Roudaut, C., Kracker, S., Mahlaoui, N., Toubert, A., Clave, E., et al. (2019). Successful in utero stem cell transplantation in X-linked severe combined immunodeficiency. *Blood Adv* 3, 237–241.

157. Westgren, M., Ringdén, O., Bartmann, P., Bui, T.-H., Lindton, B., Mattsson, J., Uzunel, M., Zetterquist, H., and Hansmann, M. (2002). Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency. *Am. J. Obstet. Gynecol.* 187, 475–482.

158. Thuy, L.P., Belmont, J., and Nyhan, W.L. (1999). Prenatal diagnosis and treatment of holocarboxylase synthetase deficiency. *Prenat. Diagn.* 19, 108–112.

159. Roth, K.S., Yang, W., Allan, L., Saunders, M., Gravel, R.A., and Dakshinamurti, K. (1982). Prenatal administration of biotin in biotin responsive multiple carboxylase deficiency. *Pediatr. Res.* 16, 126–129.

160. Ampola, M.G., Mahoney, M.J., Nakamura, E., and Tanaka, K. (1975). Prenatal therapy of a patient with vitamin-B12-responsive methylmalonic acidemia. *N. Engl. J. Med.* 293, 313–317.

161. van der Meer, S.B., Spaapen, L.J., Fowler, B., Jakobs, C., Kleijer, W.J., and Wendel, U. (1990). Prenatal treatment of a patient with vitamin B12-responsive methylmalonic acidemia. *J. Pediatr.* 117, 923–926.

162. Wendel, U., Baumgartner, R., van der Meer, S.B., and Spaapen, L.J. (1991). Accumulation of odd-numbered long-chain fatty acids in fetuses and neonates with inherited disorders of propionate metabolism. *Pediatr. Res.* 29, 403–405.

163. Evans, M.I., Duquette, D.A., Rinaldo, P., Bawle, E., Rosenblatt, D.S., Whitty, J., Quintero, R.A., and Johnson, M.P. (1997). Modulation of B12 dosage and response in fetal treatment of methylmalonic aciduria (MMA): titration of treatment dose to serum and urine MMA. *Fetal Diagn. Ther.* 12, 21–23.

164. den Hollander, B., Brands, M.M., de Boer, L., Haaxma, C.A., Lengyel, A., van Essen, P., Peters, G., Kwast, H.J.T., Klein, W.M., Coene, K.L.M., et al. (2023). Oral sialic acid

supplementation in NANS-CDG: Results of a single center, open-label, observational pilot study. *J. Inherit. Metab. Dis.* **46**, 956–971.

165. van der Crabben, S.N., Verhoeven-Duif, N.M., Brilstra, E.H., Van Maldergem, L., Coskun, T., Rubio-Gozalbo, E., Berger, R., and de Koning, T.J. (2013). An update on serine deficiency disorders. *J. Inherit. Metab. Dis.* **36**, 613–619.

166. Irons, M.B., Nores, J., Stewart, T.L., Craig, S.D., Bianchi, D.W., D’Alton, M.E., Tint, G.S., Salen, G., and Bradley, L.A. (1999). Antenatal therapy of Smith-Lemli-Opitz syndrome. *Fetal Diagn. Ther.* **14**, 133–137.

167. Svoboda, M.D., Christie, J.M., Eroglu, Y., Freeman, K.A., and Steiner, R.D. (2012). Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders. *Am. J. Med. Genet. C Semin. Med. Genet.* **160C**, 285–294.

168. Lindegaard, M.L., Wassif, C.A., Vaisman, B., Amar, M., Wasmuth, E.V., Shamburek, R., Nielsen, L.B., Remaley, A.T., and Porter, F.D. (2008). Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndrome. *Hum. Mol. Genet.* **17**, 3806–3813.

169. Srinivasaraghavan, R., Parameswaran, N., Mathis, D., Burer, C., and Plecko, B. (2018). Antiquitin Deficiency with Adolescent Onset Epilepsy: Molecular Diagnosis in a Mother of Affected Offsprings. *Neuropediatrics* **49**.

170. McNally, M.A., Johnson, J., Huisman, T.A., Poretti, A., Baranano, K.W., Baschat, A.A., and Stafstrom, C.E. (2016). SCN8A Epileptic Encephalopathy: Detection of Fetal Seizures Guides Multidisciplinary Approach to Diagnosis and Treatment. *Pediatr. Neurol.* **64**, 87–91.

171. Barnes, B.T., Procaccini, D., Crino, J., Blakemore, K., Sekar, P., Sagaser, K.G., Jelin, A.C., and Gaur, L. (2018). Maternal Sirolimus Therapy for Fetal Cardiac Rhabdomyomas. *N. Engl. J. Med.* **378**, 1844–1845.

172. Ebrahimi-Fakhari, D., Stires, G., Hahn, E., Krueger, D., and Franz, D.N. (2021). Prenatal Sirolimus Treatment for Rhabdomyomas in Tuberous Sclerosis. *Pediatr. Neurol.* **125**, 26–31.

173. Vachon-Marceau, C., Guerra, V., Jaeggi, E., Chau, V., Ryan, G., and Van Mieghem, T. (2019). In-utero treatment of large symptomatic rhabdomyoma with sirolimus. *Ultrasound Obstet. Gynecol.* **53**, 420–421.

174. Cavalheiro, S., da Costa, M.D.S., and Richtmann, R. (2021). Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report. *Childs. Nerv. Syst.* **37**, 3897–3899.

175. Walsh, C.J., Micke, K., Elfman, H., Bock, M., Harper, T., Zaretsky, M., Galan, H.L., Behrendt, N., and Putra, M. (2024). Successful antenatal treatment of MAGED2-related Bartter syndrome and review of treatment options and efficacy. *Prenat. Diagn.* **44**, 172–179.

176. Tan, H.-J., Jian, W.-Y., Lv, C., Guo, D.-W., Liao, Z.-C., Xu, H., Xiao, Y., Schiller, M., Zhuo, J.-L., Yue, S.-J., et al. (2024). Prenatal diagnosis and treatment for fetal angiotensin converting enzyme deficiency. *Prenat. Diagn.* **44**, 167–171.

177. Zidere, V., Vigneswaran, T.V., Dumitrascu-Biris, I., Regan, W., Simpson, J.M., and Homfray, T. (2022). Presentation and genetic confirmation of long QT syndrome in the fetus. *HeartRhythm Case Rep* 8, 674–678.
178. Ackerman, M.J., Siu, B.L., Sturner, W.Q., Tester, D.J., Valdivia, C.R., Makielski, J.C., and Towbin, J.A. (2001). Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. *JAMA* 286, 2264–2269.
179. Saleem, F., and Baradhi, K.M. (2023). *Adrenal Hypoplasia* (StatPearls Publishing).
180. Wesche, D., Deen, P.M.T., and Knoers, N.V.A.M. (2012). Congenital nephrogenic diabetes insipidus: the current state of affairs. *Pediatr. Nephrol.* 27, 2183–2204.
181. Monnens, L., Jonkman, A., and Thomas, C. (1984). Response to indomethacin and hydrochlorothiazide in nephrogenic diabetes insipidus. *Clin. Sci.* 66, 709–715.
182. Libber, S., Harrison, H., and Spector, D. (1986). Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. *J. Pediatr.* 108, 305–311.
183. Smyczyńska, J., Pawelak, N., Hilczer, M., and Lewiński, A. (2022). Delayed Diagnosis of Congenital Combined Pituitary Hormone Deficiency including Severe Growth Hormone Deficiency in Children with Persistent Neonatal Hypoglycemia-Case Reports and Review. *Int. J. Mol. Sci.* 23,.
184. Mellone, S., Bertelli, E., Roviglione, B., Vurchio, D., Ronzani, S., Secco, A., Felici, E., Strozzi, M.M., Schena, F., and Giordano, M. (2022). Co-Occurrence of a Pathogenic HSD3B2 Variant and a Duplication on 10q22.3-q23.2 Detected in Newborn Twins with Salt-Wasting Congenital Adrenal Hyperplasia. *Genes* 13,.
185. Cheng, S., Lo, I.F.M., and Luk, H.-M. (2023). *FAM111A-Related Skeletal Dysplasias* (University of Washington, Seattle).
186. Halperin, F., and Dluhy, R.G. (2011). Glucocorticoid-remediable aldosteronism. *Endocrinol. Metab. Clin. North Am.* 40, 333–341, viii.
187. Shaw-Smith, C., De Franco, E., Lango Allen, H., Battle, M., Flanagan, S.E., Borowiec, M., Taplin, C.E., van Alfen-van der Velden, J., Cruz-Rojo, J., Perez de Nanclares, G., et al. (2014). GATA4 mutations are a cause of neonatal and childhood-onset diabetes. *Diabetes* 63, 2888–2894.
188. Balasubramanian, M., Shield, J.P.H., Acerini, C.L., Walker, J., Ellard, S., Marchand, M., Polak, M., Vaxillaire, M., Crolla, J.A., Bunyan, D.J., et al. (2010). Pancreatic hypoplasia presenting with neonatal diabetes mellitus in association with congenital heart defect and developmental delay. *Am. J. Med. Genet. A* 152A, 340–346.
189. Scholl, U.I., Goh, G., Stöltzing, G., de Oliveira, R.C., Choi, M., Overton, J.D., Fonseca, A.L., Korah, R., Starker, L.F., Kunstman, J.W., et al. (2013). Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. *Nat. Genet.* 45, 1050–1054.

190. Alshohime, F., Martin-Fernandez, M., Temsah, M.H., Alabdulhafid, M., Le Voyer, T., Alghamdi, M., Qiu, X., Alotaibi, N., Alkahtani, A., Buta, S., et al. (2020). JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency. *N. Engl. J. Med.* **382**,.
191. Lum, S.H., Neven, B., Slatter, M.A., and Gennery, A.R. (2019). Hematopoietic Cell Transplantation for MHC Class II Deficiency. *Front Pediatr* **7**, 516.
192. Ben-Skowronek, I. (2021). IPEX Syndrome: Genetics and Treatment Options. *Genes* **12**,.
193. Engelhardt, K.R., Shah, N., Faizura-Yeop, I., Kocacik Uygun, D.F., Frede, N., Muise, A.M., Shteyer, E., Filiz, S., Chee, R., Elawad, M., et al. (2013). Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. *J. Allergy Clin. Immunol.* **131**, 825–830.
194. Haddad, E., Logan, B.R., Griffith, L.M., Buckley, R.H., Parrott, R.E., Prockop, S.E., Small, T.N., Chaisson, J., Dvorak, C.C., Murnane, M., et al. (2018). SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. *Blood* **132**, 1737–1749.
195. Bousfiha, A., Moundir, A., Tangye, S.G., Picard, C., Jeddane, L., Al-Herz, W., Rundles, C.C., Franco, J.L., Holland, S.M., Klein, C., et al. (2022). The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. *J. Clin. Immunol.* **42**, 1508–1520.
196. Dvorak, C.C., Haddad, E., Heimall, J., Dunn, E., Buckley, R.H., Kohn, D.B., Cowan, M.J., Pai, S.-Y., Griffith, L.M., Cuvelier, G.D.E., et al. (2023). The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions. *J. Allergy Clin. Immunol.* **151**, 539–546.
197. Wen, Y., Wang, J., Zhang, Q., Chen, Y., and Bao, X. (2020). The genetic and clinical characteristics of aromatic L-amino acid decarboxylase deficiency in mainland China. *J. Hum. Genet.* **65**, 759–769.
198. Sreenath Nagamani, S.C., Erez, A., and Lee, B. (2019). Argininosuccinate Lyase Deficiency (University of Washington, Seattle).
199. Donati, M.A., Malvagia, S., Pasquini, E., Morrone, A., La Marca, G., Garavaglia, B., Toniolo, D., and Zammarchi, E. (2006). Barth syndrome presenting with acute metabolic decompensation in the neonatal period. *J. Inherit. Metab. Dis.* **29**, 684.
200. Tabarki, B., Al-Shafi, S., Al-Shahwan, S., Azmat, Z., Al-Hashem, A., Al-Adwani, N., Biary, N., Al-Zawahmah, M., Khan, S., and Zuccoli, G. (2013). Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. *Neurology* **80**, 261–267.
201. Tabarki, B., Al-Hashem, A., and Alfadhel, M. (2020). Biotin-Thiamine-Responsive Basal Ganglia Disease (University of Washington, Seattle).
202. Değerliyurt, A., Gündüz, M., Ceylaner, S., Ünal, Ö., and Ünal, S. (2019). Neonatal form of biotin-thiamine-responsive basal ganglia disease. Clues to diagnosis. *Turk. J. Pediatr.* **61**, 261–266.
203. Morales Corado, J.A., Lee, C.U., and Enns, G.M. (2022). Carnitine-Acylcarnitine

Translocase Deficiency. In GeneReviews®, M.P. Adam, J. Feldman, G.M. Mirzaa, R.A. Pagon, S.E. Wallace, L.J.H. Bean, K.W. Gripp, and A. Amemiya, eds. (Seattle (WA): University of Washington, Seattle),.

204. van Karnebeek, C.D., Sly, W.S., Ross, C.J., Salvarinova, R., Yaplito-Lee, J., Santra, S., Shyr, C., Horvath, G.A., Eydoux, P., Lehman, A.M., et al. (2014). Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood. *Am. J. Hum. Genet.* *94*, 453–461.

205. Quinonez, S.C., and Lee, K.N. (2022). Citrullinemia Type I (University of Washington, Seattle).

206. Berry, G.T. (2021). Classic Galactosemia and Clinical Variant Galactosemia (University of Washington, Seattle).

207. Finckh, U., Kohlschütter, A., Schäfer, H., Sperhake, K., Colombo, J.P., and Gal, A. (1998). Prenatal diagnosis of carbamoyl phosphate synthetase I deficiency by identification of a missense mutation in CPS1. *Hum. Mutat.* *12*, 206–211.

208. Wieser, T. (2019). Carnitine Palmitoyltransferase II Deficiency (University of Washington, Seattle).

209. Quinonez, S.C., and Thoene, J.G. (2021). Dihydrolipoamide Dehydrogenase Deficiency (University of Washington, Seattle).

210. Bijarnia-Mahay, S., Bhatia, S., and Arora, V. (2019). Fructose-1,6-Bisphosphatase Deficiency (University of Washington, Seattle).

211. van Karnebeek, C.D.M., Ramos, R.J., Wen, X.-Y., Tarailo-Graovac, M., Gleeson, J.G., Skrypnik, C., Brand-Arzamendi, K., Karbassi, F., Issa, M.Y., van der Lee, R., et al. (2019). Bi-allelic GOT2 Mutations Cause a Treatable Malate-Aspartate Shuttle-Related Encephalopathy. *Am. J. Hum. Genet.* *105*, 534–548.

212. Prasun, P. (2020). Multiple Acyl-CoA Dehydrogenase Deficiency (University of Washington, Seattle).

213. Van Hove, J.L.K., Coughlin, C., II, Swanson, M., and Hennermann, J.B. (2019). Nonketotic Hyperglycinemia (University of Washington, Seattle).

214. Civit, A., Gueguen, P., Blasco, H., Benz-de-Bretagne, I., Lebredonchel, É., Dingo, G., Jeanne, M., Rouxel, S., Tardieu, M., Raynor, A., et al. (2023). Sweet ending: When genetics prevent a dramatic CDG diagnostic mistake. *Clin. Chim. Acta* *551*, 117620.

215. Larochelle, J., Alvarez, F., Bussi eres, J.-F., Chevalier, I., Dallaire, L., Dubois, J., Faucher, F., Fenyves, D., Goodyer, P., Grenier, A., et al. (2012). Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Qu ebec. *Mol. Genet. Metab.* *107*, 49–54.

216. Thompson, S., Hertzog, A., Selvanathan, A., Batten, K., Lewis, K., Nisbet, J., Mitchell, A., Dalkeith, T., Billmore, K., Moore, F., et al. (2023). Treatment of HMG-CoA Lyase Deficiency- Longitudinal Data on Clinical and Nutritional Management of 10 Australian Cases. *Nutrients* *15*,

217. Wolf, B. (2023). Biotinidase Deficiency (University of Washington, Seattle).
218. Wild, K.T., Ganetzky, R.D., Yudkoff, M., and Ierardi-Curto, L. (2019). Hyperornithinemia, Hyperammonemia, and Homocitrullinuria Syndrome Causing Severe Neonatal Hyperammonemia. *JIMD Rep.* 44, 103–107.
219. Walder, R.Y., Shalev, H., Brennan, T.M., Carmi, R., Elbedour, K., Scott, D.A., Hanauer, A., Mark, A.L., Patil, S., Stone, E.M., et al. (1997). Familial hypomagnesemia maps to chromosome 9q, not to the X chromosome: genetic linkage mapping and analysis of a balanced translocation breakpoint. *Hum. Mol. Genet.* 6, 1491–1497.
220. Bor, M., Ilhan, O., Gumus, E., Ozkan, S., and Karaca, M. (2022). A Newborn with Infantile-Onset Pompe Disease Improving after Administration of Enzyme Replacement Therapy: Case Report. *Pediatr. Crit. Care Med.* 11, 62–66.
221. Mütze, U., Reischl-Hajjibadi, A., and Kölker, S. (2024). Classic Isovaleric Acidemia (University of Washington, Seattle).
222. Muru, K., Reinson, K., Künnapas, K., Lilleväli, H., Nochi, Z., Mosegaard, S., Pajusalu, S., Olsen, R.K.J., and Öunap, K. (2019). FLAD1-associated multiple acyl-CoA dehydrogenase deficiency identified by newborn screening. *Mol Genet Genomic Med* 7, e915.
223. Prasun, P., LoPiccolo, M.K., and Ginevic, I. (2022). Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency / Trifunctional Protein Deficiency (University of Washington, Seattle).
224. Strauss, K.A., Puffenberger, E.G., and Carson, V.J. (2020). Maple Syrup Urine Disease (University of Washington, Seattle).
225. Ahrens-Nicklas, R.C., Pyle, L.C., and Ficicioglu, C. (2016). Morbidity and mortality among exclusively breastfed neonates with medium-chain acyl-CoA dehydrogenase deficiency. *Genet. Med.* 18, 1315–1319.
226. Martinelli, D., Travaglini, L., Drouin, C.A., Ceballos-Picot, I., Rizza, T., Bertini, E., Carrozzo, R., Petrini, S., de Lonlay, P., El Hachem, M., et al. (2013). MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. *Brain* 136, 872–881.
227. Kaler, S.G., Holmes, C.S., Goldstein, D.S., Tang, J., Godwin, S.C., Donsante, A., Liew, C.J., Sato, S., and Patronas, N. (2008). Neonatal diagnosis and treatment of Menkes disease. *N. Engl. J. Med.* 358, 605–614.
228. Haack, T.B., Danhauser, K., Haberberger, B., Hoser, J., Strecker, V., Boehm, D., Uziel, G., Lamantea, E., Invernizzi, F., Poulton, J., et al. (2010). Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. *Nat. Genet.* 42, 1131–1134.
229. Peters, H., Buck, N., Wanders, R., Ruitter, J., Waterham, H., Koster, J., Yapliito-Lee, J., Ferdinandusse, S., and Pitt, J. (2014). ECHS1 mutations in Leigh disease: a new inborn error of metabolism affecting valine metabolism. *Brain* 137, 2903–2908.
230. Schwahn, B.C., van Spronsen, F., Misko, A., Pavaine, J., Holmes, V., Spiegel, R., Schwarz, G., Wong, F., Horman, A., Pitt, J., et al. (2024). Consensus guidelines for the

diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. *J. Inherit. Metab. Dis.* *47*, 598–623.

231. Misko, A., Mahtani, K., Abbott, J., Schwarz, G., and Atwal, P. (2023). Molybdenum Cofactor Deficiency (University of Washington, Seattle).

232. Girard, M., Douillard, C., Debray, D., Lacaille, F., Schiff, M., Vuillaumier-Barrot, S., Dupré, T., Fabre, M., Damaj, L., Kuster, A., et al. (2020). Long term outcome of MPI-CDG patients on D-mannose therapy. *J. Inherit. Metab. Dis.* *43*, 1360–1369.

233. Valayannopoulos, V., Nicely, H., Harmatz, P., and Turbeville, S. (2010). Mucopolysaccharidosis VI. *Orphanet J. Rare Dis.* *5*, 5.

234. Bachmann, C., Krähenbühl, S., Colombo, J.P., Schubiger, G., Jaggi, K.H., and Tönz, O. (1981). N-acetylglutamate synthetase deficiency: a disorder of ammonia detoxication. *N. Engl. J. Med.* *304*, 543.

235. Kaczmarczyk, A., Baker, M., Diddle, J., Yuzyuk, T., Valle, D., and Lindstrom, K. (2022). A neonate with ornithine aminotransferase deficiency; insights on the hyperammonemia-associated biochemical phenotype of gyrate atrophy. *Mol Genet Metab Rep* *31*, 100857.

236. Mew, N.A., Simpson, K.L., Gropman, A.L., Lanpher, B.C., Chapman, K.A., and Summar, M.L. (2017). Urea Cycle Disorders Overview (University of Washington, Seattle).

237. Lichter-Konecki, U., Caldovic, L., Morizono, H., Simpson, K., Mew, N.A., and MacLeod, E. (2022). Ornithine Transcarbamylase Deficiency (University of Washington, Seattle).

238. Conte, F., Morava, E., Bakar, N.A., Wortmann, S.B., Poerink, A.J., Grunewald, S., Crushell, E., Al-Gazali, L., de Vries, M.C., Mørkrid, L., et al. (2020). Phosphoglucomutase-1 deficiency: Early presentation, metabolic management and detection in neonatal blood spots. *Mol. Genet. Metab.* *131*, 135–146.

239. Bedoyan, J.K., Hage, R., Shin, H.K., Linard, S., Ferren, E., Ducich, N., Wilson, K., Lehman, A., Schillaci, L.-A., Manickam, K., et al. (2020). Utility of specific amino acid ratios in screening for pyruvate dehydrogenase complex deficiencies and other mitochondrial disorders associated with congenital lactic acidosis and newborn screening prospects. *JIMD Rep.* *56*, 70–81.

240. Shchelochkov, O.A., Carrillo, N., and Venditti, C. (2016). Propionic Acidemia (University of Washington, Seattle).

241. Plecko, B., Zweier, M., Begemann, A., Mathis, D., Schmitt, B., Striano, P., Baethmann, M., Vari, M.S., Beccaria, F., Zara, F., et al. (2017). Confirmation of mutations in PROSC as a novel cause of vitamin B 6 -dependent epilepsy. *J. Med. Genet.* *54*, 809–814.

242. Witters, P., Tahata, S., Barone, R., Öunap, K., Salvarinova, R., Grønborg, S., Hoganson, G., Scaglia, F., Lewis, A.M., Mori, M., et al. (2020). Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG. *Genet. Med.* *22*, 1102–1107.

243. Kodera, H., Nakamura, K., Osaka, H., Maegaki, Y., Haginoya, K., Mizumoto, S., Kato, M., Okamoto, N., Iai, M., Kondo, Y., et al. (2013). De novo mutations in SLC35A2 encoding a UDP-

galactose transporter cause early-onset epileptic encephalopathy. *Hum. Mutat.* **34**, 1708–1714.

244. Grünert, S.C., Foster, W., Schumann, A., Lund, A., Pontes, C., Roloff, S., Weinhold, N., Yue, W.W., AlAsmari, A., Obaid, O.A., et al. (2021). Succinyl-CoA:3-oxoacid coenzyme A transferase (SCOT) deficiency: A rare and potentially fatal metabolic disease. *Biochimie* **183**, 55–62.

245. Leslie, N.D., and Saenz-Ayala, S. (2023). Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency (University of Washington, Seattle).

246. Steinfeld, R., Grapp, M., Kraetzner, R., Dreha-Kulaczewski, S., Helms, G., Dechent, P., Wevers, R., Grosso, S., and Gärtner, J. (2009). Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. *Am. J. Hum. Genet.* **85**, 354–363.

247. Yarahmadi, S.G., and Morovvati, S. (2022). CAD gene and early infantile epileptic encephalopathy-50; three Iranian deceased patients and a novel mutation: case report. *BMC Pediatr.* **22**, 125.

248. Li, Z., and Wang, H. (2021). Molecular Mechanisms of the SLC13A5 Gene Transcription. *Metabolites* **11**,.

249. Wang, D., Pascual, J.M., and De Vivo, D. (2018). Glucose Transporter Type 1 Deficiency Syndrome (University of Washington, Seattle).

250. Göpel, W., Berkowski, S., Preuss, M., Ziegler, A., Küster, H., Felderhoff-Müser, U., Gortner, L., Mögel, M., Härtel, C., Herting, E., et al. (2014). Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants. *BMC Pediatr.* **14**, 210.

251. Rahman, S., Ecob, R., Costello, H., Sweeney, M.G., Duncan, A.J., Pearce, K., Strachan, D., Forge, A., Davis, A., and Bitner-Glindzicz, M. (2012). Hearing in 44-45 year olds with m.1555A>G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort study. *BMJ Open* **2**, e000411.

252. Kuersten, M., Tacke, M., Gerstl, L., Hoelz, H., Stülpnagel, C.V., and Borggraefe, I. (2020). Antiepileptic therapy approaches in KCNQ2 related epilepsy: A systematic review. *Eur. J. Med. Genet.* **63**, 103628.


253. Dilena, R., Striano, P., Traverso, M., Viri, M., Cristofori, G., Tadini, L., Barbieri, S., Romeo, A., and Zara, F. (2016). Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation. *Brain Dev.* **38**, 128–131.

254. Michael, M., Harvey, E., Milliner, D.S., Frishberg, Y., Sas, D.J., Calle, J., Copelovitch, L., Penniston, K.L., Saland, J., Somers, M.J.G., et al. (2024). Diagnosis and management of primary hyperoxalurias: best practices. *Pediatr. Nephrol.*

255. Cooney, A.L., Wambach, J.A., Sinn, P.L., and McCray, P.B., Jr (2021). Gene Therapy Potential for Genetic Disorders of Surfactant Dysfunction. *Front Genome Ed* **3**, 785829.

Figure titles and legends

Figure 1. Methods of delivering fetal therapy in humans and animal models (created with Biorender).



Tables

Table 1. Selection criteria for genes associated with actionable fetal disorders

| Topic | Selection criteria |
|--------------------------------|---|
| Age of treatment initiation | Therapy administered <i>in utero</i> or in the first week of life is expected to prevent morbidity, mortality, or irreversible organ damage to the infant |
| Safety and efficacy of therapy | Therapy is safe and plausibly effective |
| Clinical severity | Gene is associated with critical illness or chronic disease |
| Gene-disease validity | Genes with limited, disputed, or refuted ClinGen validity scores have been excluded |

Table 2. Genes associated with disorders with *in utero* fetal therapies in clinical trials and case reports (n = 53).

| Phenotype | OMIM | Gene | Inheritance | ClinGen gene-disease validity | Fetal therapy | Level of evidence | Clinical Area |
|---|--------|----------------------|-------------|-------------------------------|--|---|------------------------------|
| <i>Clinical trials</i> | | | | | | | |
| Osteogenesis Imperfecta type III or severe type IV | 259420 | <i>COL1A1</i> | AD | Definitive | Prenatal administration of allogeneic expanded fetal mesenchymal stem cells | Clinical trial (NCT03706482) | Endocrine disorder |
| | 166220 | <i>COL1A2</i> | AD | Definitive | | | |
| Hemoglobin Bart's hydrops fetalis (subset of alpha thalassemia) | 236750 | <i>HBA1 and HBA2</i> | AR | Definitive | In utero transfusions ^{92, 93} Intravascular intrauterine exchange transfusion ^{94, 95} <i>In utero</i> HSCT ⁹⁶ Intrauterine red cell and paternal CD34+ cells transfusion ^{97, 98} | Clinical trials (NCT05797272, NCT02986698) Case reports | Hematologic Disorder |
| Infantile-onset Pompe disease | 232300 | <i>GAA</i> | AR | Definitive | Prenatal ERT ⁴⁶ ; gene therapy ¹³⁷ | Clinical trial (NCT04532047) for prenatal ERT; mouse model for gene therapy | Inherited metabolic disorder |
| Lysosomal acid lipase deficiency | 620151 | <i>LIPA</i> | AR | Definitive | Prenatal ERT ⁴⁶ | Clinical trial (NCT04532047) | Inherited metabolic disorder |
| Mucopolysaccharidosis 1 (Hurler) | 607014 | <i>IDUA</i> | AR | Definitive | Prenatal ERT ⁴⁶ ; HSC gene therapy ⁷⁷ ; Retrovirus gene therapy ¹³⁸ ; base editing ¹³⁹ | Clinical trial for prenatal ERT (NCT04532047); canine model HSC gene therapy (limited success); | Inherited metabolic disorder |

| | | | | | | | |
|--|----------------------------|--|----------------|--------------------------------------|--|--|------------------------------|
| | | | | | | canine retrovirus gene therapy (limited success); <i>in utero</i> base editing mouse model | |
| Mucopolysacch aridosis 2 (Hunter) | 309900 | <i>IDS</i> | XL | Definitive | Prenatal ERT ⁴⁶ | Clinical trial (NCT045320 47) | Inherited metabolic disorder |
| Mucopolysacch aridosis 4a (Morquio) | 253000 | <i>GALNS</i> | AR | Definitive | Prenatal ERT ⁴⁶ | Clinical trial (NCT045320 47) | Inherited metabolic disorder |
| Mucopolysacch aridosis 6 (Maroteaux-Lamy) | 253200 | <i>ARSB</i> | AR | Definitive | Prenatal ERT ⁴⁶ | Clinical trial (NCT045320 47) | Inherited metabolic disorder |
| Mucopolysacch aridosis 7 (Sly) | 253220 | <i>GUSB</i> | AR | Definitive | Prenatal ERT ⁴⁶ ; gene therapy ¹⁴⁰⁻¹⁴³ | Clinical trial for prenatal ERT (NCT045320 47); mouse model gene therapy | Inherited metabolic disorder |
| Neuronopathic Gaucher disease | 231000 | <i>GBA</i> | AR | Definitive | Prenatal ERT ⁴⁶ ; gene therapy ¹⁴⁴ | Clinical trial for prenatal ERT (NCT045320 47); animal model gene therapy | Inherited metabolic disorder |
| X-linked hypohidrotic ectodermal dysplasia | 305100 | <i>EDA</i> | XL | No VS | Protein administered via intra-amniotic injection ^{68,145} | Clinical trial (NCT049806 38) | Multi-system disorder |
| <i>Case reports and case series</i> | | | | | | | |
| Long QT syndrome | 613688 603830 618447 | <i>KCNH2</i> <i>SCN5A</i> <i>CACNA1C</i> | AD AD AD | Definitive Definitive Moderate | Transplacenta l pharmacother apy with intravenous magnesium and lidocaine (delivered to mother) ¹⁴⁶ | Human case reports ¹⁴⁶ | Cardiac disorder |

| | | | | | | | |
|---|--|--|---|--|---|--|--------------------------|
| | | | | | Prenatal administration of beta-blockers could lessen the frequency of VT ¹⁴⁷⁻¹⁵⁰ | | |
| Goitrous hypothyroidism | 274500 | <i>TPO</i> | AR | No VS | Intra-amniotic administrations of LT4 ¹⁵¹ | Human case report | Endocrine disorder |
| MCT8 deficiency (Allan-Herndon-Dudley Syndrome) | 300523 | <i>SLC16A2</i> | XL | Definitive | Weekly intra-amniotic instillation of LT4 ¹⁵² | Human case report | Endocrine disorder |
| Diamond-Blackfan anemia | 105650 612561 613308 612562 | <i>RPS19</i> <i>RPL5</i> <i>RPS10</i> <i>RPS24</i> | AD AD AD AD | Definitive Definitive Definitive Definitive | In utero blood transfusion ⁹¹ | Human case report | Hematologic disorder |
| Factor deficiencies FI (Fibrinogen) FII (Prothrombin) FV FVII VIII (Hemophilia A) FIX (Hemophilia B) FX FXI (Hemophilia C) FXII FXIII | 202400 613679 227400 227500 306700 306900 227600 612416 234000 613225 613235 | <i>FGB, FGA, FGG</i> <i>F2</i> <i>F5</i> <i>F7</i> <i>F8</i> <i>F9</i> <i>F10</i> <i>F11</i> <i>F12</i> <i>F13A1</i> <i>F13B</i> | AR AR AR AR XL XL AR AD;AR AR AR AR | Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive | Consideration of C-section delivery and avoidance of vacuum assistance or forceps to avoid intracranial hemorrhage ^{76, 103} For Hemophilia A, administration of hAFMSCs via <i>in utero</i> transplantation ¹⁵³ | Human case reports Animal model | Hematologic disorder |
| <i>GATA1</i> -positive transient abnormal myelopoiesis | 159595 | <i>GATA1</i> | Somatic | No VS | Serial <i>in utero</i> blood transfusion ¹⁵⁴ | Human case report | Hematologic disorder |
| Severe combined immunodeficiency | 300400 | <i>IL2RG</i> | XL | Definitive | <i>In utero</i> transplantation of paternal bone marrow ^{155, 156} | Human case reports | Inborn error of immunity |

| | | | | | | | |
|---|----------------------------|---|----------------|--|--|--|------------------------------|
| | | | | | <i>In utero</i> transplantation of cryopreserved fetal liver cells ¹⁵⁷ | | |
| Cobalamin C deficiency | 277400 | <i>MMACHC</i> | AR | Definitive | Maternal hydroxocobalamin and possible folic acid and L-carnitine ⁷⁰⁻⁷² | Human case reports | Inherited metabolic disorder |
| Holocarboxylase synthetase deficiency | 253270 | <i>HLCS</i> | AR | Definitive | Maternal treatment with biotin ^{158,159} | Human case reports | Inherited metabolic disorder |
| (Vitamin B12-responsive) Methylmalonic acidemia | 251100 251110 277410 | <i>MMAA</i> <i>MMAB</i> <i>MMADHC</i> | AR AR AR | Definitive Definitive Definitive | Maternal vitamin B12 ¹⁶⁰⁻¹⁶³ | Human case reports | Inherited metabolic disorder |
| NANS-CDG, congenital disorder of glycosylation | 610442 | <i>NANS</i> | AR | No VS | Maternal treatment with oral sialic acid ¹⁶⁴ | Human case report | Inherited metabolic disorder |
| 3-PGDH deficiency | 601815 | <i>PHGDH</i> | AR | Definitive | Maternal L-serine treatment ¹⁶⁵ | Human case report | Inherited metabolic disorder |
| Smith-Lemli-Opitz syndrome | 270400 | <i>DHCR7</i> | AR | Definitive | Human antenatal cholesterol supplementation through fetal intravenous and intraperitoneal transfusions of fresh frozen plasma ^{166,167} ; <i>in utero</i> delivery of LXR-agonist that induces <i>Abca1</i> , mouse model ¹⁶⁸ | Human case reports; Animal model ¹⁶⁷ | Inherited metabolic disorder |
| Transient infantile liver failure | 613070 | <i>TRMU</i> | AR | Moderate | Maternal cysteine supplementation ⁶⁹ | Human case series | Inherited metabolic disorder |

| | | | | | | | |
|--------------------------------|------------------|--------------|----------|--------------------------|---|--------------------|---------------------|
| ALDH7A1-related epilepsy | 266100 | ALDH7A1 | AR | Definitive | Affected mother and fetus, treated with pyridoxine during pregnancy resulting in healthy seizure-free affected child ¹⁶⁹ | Human case report | Neurologic disorder |
| SCN8A epileptic encephalopathy | 614558 | SCN8A | AD | Definitive | Maternal administration of levetiracetam ¹⁷⁰ | Human case report | Neurologic disorder |
| Tuberous sclerosis complex | 191100 613254 | TSC1 TSC2 | AD AD | Definitive Definitive | Maternal sirolimus ¹⁷¹⁻¹⁷³ Maternal everolimus ¹⁷⁴ | Human case reports | Neurologic disorder |
| Bartter syndrome | 300971 | MAGED2 | XL | No VS | Amnioreduction ¹⁷⁵ | Human case report | Renal disorder |
| Renal tubular dysgenesis | 267430 | ACE | AR | No VS | Serial amnioinfusions ¹⁷⁶ | Human case report | Renal disorder |
| Cystic fibrosis | 219700 | CFTR | AR | No VS | Maternal administration of CFTR modulator therapy ^{47,48,49} | Human case reports | Pulmonary disorder |

Abbreviations: AD: Autosomal dominant; AR: Autosomal recessive; ERT: Enzyme replacement therapy; hAFMSCs: Human amniotic fluid mesenchymal stromal cells; HSC: Hematopoietic stem cells; HSCT: Hematopoietic stem cell transplantation; LT4: Levothyroxine; LXR-agonist: Liver X receptor agonist; VS: Validity score; VT: Ventricular tachycardia; XL: X-linked

Table 3. Genes associated with disorders with clinically available therapies that could be applied in the first week of life (n = 267).

| Phenotype | OMIM | Gene | Inheritance | ClinGen gene-disease validity | Treatment | Reason for early detection |
|--|--|---|--|--|--|--|
| <i>Cardiac disorders</i> | | | | | | |
| Long QT syndrome | 613688 192500 603830 | <i>KCNH2</i> <i>KCNQ1</i> <i>SCN5A</i> | AD AD AD | Definitive Definitive Definitive | Beta blockers, implantable cardioverter-defibrillator | Long QT can present as early as fetal life ¹⁷⁷ and result in infant death ¹⁷⁸ |
| <i>Endocrine disorders</i> | | | | | | |
| ACTH signaling defects | 201400 609734 607398 600955 | <i>TBX19</i> <i>POMC</i> <i>MRAP</i> <i>PCSK1</i> | AR AR AR AR | No VS No VS No VS No VS | Hydrocortisone | Salt-wasting crises or hypoglycemia can present in the first days of life ⁸¹ |
| Adrenal hypoplasia | 300200 184757 | <i>NR0B1</i> <i>NR5A1</i> | XL AR | No VS No VS | Hydrocortisone, fludrocortisone, and salt supplementation ¹⁷⁹ | Salt-wasting crises can present in the first days of life |
| AVP resistance (formerly nephrogenic diabetes insipidus) | 304800 125800 | <i>AVPR2</i> <i>AQP2</i> | XL AD;AR | No VS No VS | Low-solute diet ¹⁸⁰ , Thiazide diuretics ¹⁸¹ , DDAVP and NSAIDs ¹⁸² | Can present with hypovolemic shock in the first days of life |
| Central hypothyroidism | 275100 618573 300888 | <i>TSHB</i> <i>TRHR</i> <i>IGSF1</i> | AR AR XL | No VS No VS No VS | Levothyroxine | Can be missed on newborn screen due to absence of TSH elevation, delayed treatment can lead to permanent neurological damage |
| Combined pituitary hormone deficiency | 312000 613038 182230 262600 221750 262700 613986 | <i>SOX3</i> <i>POU1F1</i> <i>HESX1</i> <i>PROP1</i> <i>LHX3</i> <i>LHX4</i> <i>OTX2</i> | XL AD;AR AD;AR AR AR AD AD | Moderate No VS No VS No VS No VS No VS No VS | rhGH, hydrocortisone, and LT4 ¹⁸³ | Can present with neonatal hypoglycemia ¹⁸³ |
| Congenital adrenal hyperplasia | 201910 201810 201710 613743 | <i>CYP21A2</i> <i>HSD3B2</i> <i>STAR</i> <i>CYP11A1</i> | AR AR AR AR | No VS No VS No VS No VS | Hydrocortisone, fludrocortisone, sodium supplementation | Salt-wasting crises can present in the first days of life ¹⁸⁴ |
| Congenital hyperinsulinism | 601820 256450 | <i>KCNJ11</i> <i>ABCC8</i> | AD;AR AD;AR | No VS No VS | Diazoxide, somatostatin analogs, | Hypoglycemia can present in the first |

| | | | | | | |
|--|--|---|---|---|--|---|
| | 602485 606762 125850 600496 | <i>GCK</i> <i>GLUD1</i> <i>HNF4A</i> <i>HNF1A</i> | AD AD AD AD | No VS No VS No VS No VS | pancreatectomy for resistant forms; paternal inheritance of recessive <i>KCNJ11</i> or <i>ABCC8</i> variant leads to focal hyperinsulinism which can be treated with resection of lesion | days of life, can lead to permanent neurologic injury |
| <i>FAM111A</i> -related skeletal dysplasia | 127000 | <i>FAM111A</i> | AD | No VS | Magnesium, calcium, calcitriol or alfacalcidol | Primary hypoparathyroidism, hypocalcemia, and seizures may develop in the first days of life ¹⁸⁵ |
| Hyperaldosteronism | 103900 605635 613677 | <i>CYP11B1/</i> <i>CYP11B2</i> <i>CLCN2</i> <i>KCNJ5</i> | AD AD AD | No VS No VS No VS | Antihypertensive therapies with glucocorticoids or mineralocorticoid receptor antagonists ¹⁸⁶ | Hypertension and electrolyte abnormalities may develop in the first week of life |
| Hypoaldosteronism | 203400 | <i>CYP11B2</i> | AR | Definitive | Fludrocortisone | Salt-wasting can develop in the first days of life ⁸² |
| Infantile diabetes mellitus | 618856 618857 618858 614430 600001 615710 606176 606392 609069 601410 226980 N/A 614231 610199 N/A 227810 N/A N/A 615952 | <i>KCNJ11</i> <i>ABCC8</i> <i>INS</i> <i>GATA4</i> <i>GATA6</i> <i>RFX6</i> <i>GCK</i> <i>PDX1</i> <i>PTF1A</i> <i>ZFP57</i> <i>EIF2AK3</i> <i>NEUROG3</i> <i>IER3IP1</i> <i>GLIS3</i> <i>PAX6</i> <i>SLC2A2</i> <i>NKX2-2</i> <i>MNX1</i> <i>STAT3</i> | AD AD;AR AD;AR AD AD AR AR AD AR AD;AR AR AR AR AR AD AR AR AR AD | Definitive Definitive Definitive Definitive Definitive Definitive Definitive Moderate No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS | Insulin, pancreatic enzymes | Diabetes can present within the first days of life ^{187,188} |
| Neonatal severe hyperparathyroidism | 239200 | <i>CASR</i> | AD;AR | Definitive | Cinacalcet, parathyroidectomy | Presents with severe hypercalcemia, hypotonia, respiratory failure. Can be inherited AR or transient AD form if inherited from father |

| | | | | | | |
|--|--|---|----------------------------|---|---|--|
| Permanent neonatal hyperthyroidism | 609152 | <i>TSHR</i> | AD | No VS | Methimazole, thyroidectomy, or radioablation | Delayed diagnosis can lead to craniosynostosis and neurologic injury |
| Primary aldosteronism | 177735 620126 264350 615474 620125 | <i>NR3C2</i> <i>SCNN1G</i> <i>SCNN1A</i> <i>CACNA1D</i> <i>SCNN1B</i> | AD AR AR AD AR | Definitive Definitive Strong Moderate No VS | NaCl, calcium channel blocker, clonidine, spironolactone, depending on genotype | Hypertension and heart block may present in the first days of life ¹⁸⁹ |
| <i>Gastrointestinal disorders</i> | | | | | | |
| Congenital chloride diarrhea | 214700 | <i>SLC26A3</i> | AR | No VS | Omeprazole, fluid management, chloride, sodium, potassium, sodium butyrate | Diarrhea can develop in the first days of life and cause severe electrolyte abnormalities |
| Congenital sodium diarrhea | 616868 614665 | <i>SLC9A3</i> <i>GUCY2C</i> | AR AD | No VS No VS | Sodium, bicarbonate, fluid management | Diarrhea can develop in the first days of life and cause severe electrolyte abnormalities ⁸⁶ |
| Congenital sucrase-isomaltase deficiency | 222900 | <i>SI</i> | AR | No VS | Avoidance of sucrose and isomaltose | Getting sucrose in the first days of life (e.g. from a sweetened medication) could cause serious diarrhea, dehydration, or electrolyte abnormalities |
| Diarrhea with microvillus atrophy, with or without cholestasis | 251850 | <i>MYO5B</i> | AR | No VS | Fluid and electrolyte management | Diarrhea can develop in the first days of life and cause severe electrolyte abnormalities |
| Glucose-galactose malabsorption | 606824 | <i>SLC5A1</i> | AR | No VS | Elimination of glucose and galactose from diet | Diarrhea can develop in the first days of life and cause severe electrolyte abnormalities ⁸⁷ |
| GPIHBP1 deficiency | 615947 | <i>GPIHBP1</i> | AR | No VS | Volanesorsen, fat-restricted diet | Chylomicronemia can develop in the first days of life ⁹⁰ |

| <i>Hematologic disorders</i> | | | | | | |
|-------------------------------------|--|--|---|--|---|--|
| Coagulation factor deficiencies | 613679 227400 227500 306700 306900 227600 612416 234000 613225 613235 202400 202400 202400 | <i>F2</i> <i>F5</i> <i>F7</i> <i>F8</i> <i>F9</i> <i>F10</i> <i>F11</i> <i>F12</i> <i>F13A1</i> <i>F13B</i> <i>FGG</i> <i>FGB</i> <i>FGA</i> | AR AR AR XL XL AR AD;AR AR AR AR AR AR AR | Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive | Plasma product therapy, replacement of appropriate factor | Diagnosis may lead to prompt and appropriate treatment of intracranial hemorrhage or cephalohematoma |
| Erythropoietic protoporphyrias | 177000 263700 | <i>FECH</i> <i>UROS</i> | AR AR | Definitive No VS | Avoidance of phototherapy, blood transfusion, splenectomy | Jaundice and hepatosplenomegaly can develop in the first days of life; phototherapy causes severe blistering ⁹⁹ |
| Severe congenital neutropenias | 214500 | <i>LYST</i> | AR | Definitive | GM-CSF therapy, HSCT ¹⁰² | Growth factor reduces the frequency and severity of infection |
| Severe congenital thrombocytopenias | 616738 604498 620481 274000 | <i>MECOM</i> <i>MPL</i> <i>THPO</i> <i>RBM8A</i> | AD AR AR AR | Definitive Definitive No VS No VS | Platelet transfusions, Rituximab, ¹⁰⁰ HSCT ¹⁰¹ | Bleeding episodes may begin in the first days of life |
| <i>Inborn errors of immunity</i> | | | | | | |
| Agammaglobulinemia | 613502 300755 613501 601495 616941 619824 619705 | <i>BLNK</i> <i>BTK</i> <i>CD79A</i> <i>IGHM</i> <i>TCF3</i> <i>FNIP1</i> | AR XL AR AR AD;AR AR | Definitive Definitive Definitive Definitive Definitive Definitive Strong | HSCT, replacement immunoglobulin treatment, aggressive antibiotic therapy for documented or suspected infections, measures to avoid infection, monitor pulmonary status ⁵⁶ | Earlier diagnosis and treatment would likely prevent morbidity and mortality ¹⁰⁵ |
| Autoinflammatory disorders | 616050 612852 607115 617397 | <i>NLRC4</i> <i>IL1RN</i> <i>NLRP3</i> <i>USP18</i> | AD AR AD AR | No VS No VS No VS No VS | r-hIL-18BP Anakinra, etanercept, methotrexate, corticosteroid Anakinra ⁵⁶ Ruxolitinib ¹⁹⁰ | Early treatment may improve autoinflammation, in severe cases, fatal if untreated ^{107,108,190} |
| Combined immunodeficiencies | 606843 308230 209920 243700 | <i>CD40</i> <i>CD40L</i> <i>CIITA</i> <i>DOCK8</i> | AR XL AR AR | Definitive Definitive Definitive Definitive | HSCT ¹⁹¹ , immune prophylaxis | Can present as SCID, in severe cases, fatal if untreated ¹⁰⁷ |

| | | | | | | |
|--|--|---|--|--|---|--|
| | 616873 300636 620815 620816 620817 250250 147060 301000 269840 615758 615816 | <i>IKZF1</i> <i>IKBKG</i> <i>RFXANK</i> <i>RFX5</i> <i>RFXAP</i> <i>RMRP</i> <i>STAT3</i> <i>WAS</i> <i>ZAP70</i> <i>LCK</i> <i>PGM3</i> | AD XL AR AR AR AR AD XL AR AR AR | Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Moderate No VS | | |
| Congenital defects of phagocyte number, function or both | 233690 618935 233700 233710 613960 306400 116920 | <i>CYBA</i> <i>CYBC1</i> <i>NCF1</i> <i>NCF2</i> <i>NCF4</i> <i>CYBB</i> <i>ITGB2</i> | AR AR AR AR AR XL AR | No VS No VS No VS No VS No VS No VS No VS | HSCT, immune prophylaxis, interferon gamma | Decrease morbidity and mortality with immune prophylaxis and interferon gamma ¹⁰⁷ |
| Defects in intrinsic and innate immunity | 607676 612260 | <i>IRAK4</i> <i>MYD88</i> | AR AR | No VS No VS | Immune prophylaxis | Decrease morbidity and mortality with immune prophylaxis ¹⁰⁷ |
| Diseases of immune dysregulation | 614700 601859 304790 603553 607624 603552 613101 608898 601859 613148 612567 308240 300079 | <i>LRBA</i> <i>FASLG</i> <i>FOXP3</i> <i>PRF1</i> <i>RAB27A</i> <i>STX11</i> <i>STXBP2</i> <i>UNC13D</i> <i>FAS</i> <i>IL10RA</i> <i>IL10RB</i> <i>SH2D1A</i> <i>XIAP</i> | AR AR XL AR AR AR AR AR AD AR AR XL XL | Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive No VS No VS No VS No VS No VS | HSCT, Abatacept HSCT, Rapamycin ¹⁹² HSCT, Rapamycin ¹⁹² HSCT, Emapalumab HSCT, Emapalumab HSCT, Emapalumab HSCT, Emapalumab HSCT, Emapalumab HSCT, Rapamycin ¹⁹² HSCT ¹⁹³ HSCT ¹⁹³ HSCT, Emapalumab HSCT, Emapalumab | Targeted treatment ^{107,108} |
| Severe combined immunodeficiencies | 102700 267500 615617 615615 610163 615401 602450 300400 608971 600802 619374 606593 300988 611291 615966 619924 601457 601457 243150 | <i>ADA</i> <i>AK2</i> <i>CD3D</i> <i>CD3E</i> <i>CD247</i> <i>CORO1A</i> <i>DCLRE1C</i> <i>IL2RG</i> <i>IL7R</i> <i>JAK3</i> <i>LCP2</i> <i>LIG4</i> <i>MSN</i> <i>NHEJ1</i> <i>PRKDC</i> <i>PTPRC</i> <i>RAG1</i> <i>RAG2</i> <i>TTC7A</i> | AR AR AR AR AR AR AR XL AR AR AR AR XL AR AR AR AR AR AR | Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive Definitive | HSCT ¹⁹⁴ , immune prophylaxis | Fatal if untreated ^{195,196} |

| | | | | | | |
|--|------------------|-----------------------------|----------|--------------------------|--|--|
| | 617514 618986 | <i>LAT</i> <i>RAC2</i> | AR AD | Strong Strong | | |
| Thymic defects | 601705 615560 | <i>FOXP1</i> <i>PAX1</i> | AR AR | Definitive Definitive | Thymus transplant, immune prophylaxis ⁵⁶ | Susceptibility to infection begins immediately after birth |
| <i>Inherited metabolic disorders</i> | | | | | | |
| AADC deficiency | 237300 | <i>DDC</i> | AR | Definitive | Pyridoxine or pyridoxal phosphate, folinic acid, dopamine agonists, SSRIs, 5- HTP, MAO-B inhibitors | Oculogyric crisis may present as early as 1 month, and is often misdiagnosed as seizure, resulting in inappropriate care; ¹⁹⁷ early treatment may prevent neurologic regression and development of seizures |
| Argininosuccinate lyase deficiency | 207900 | <i>ASL</i> | AR | Definitive | Low-protein diet, dextrose- containing fluids, and ammonia scavenger medications as needed | Hyperammonemia may develop in the first days of life ¹⁹⁸ |
| Barth syndrome | 302060 | <i>TFAZZIN</i> | XL | Definitive | Elamipretide, cornstarch, G-CSF | Acute neonatal presentation has been reported ¹⁹⁹ |
| Biotin-thiamine responsive basal ganglia disease | 607483 | <i>SLC19A3</i> | AR | Definitive | Oral biotin and thiamine ²⁰⁰ | Treatment is benign and may prevent basal ganglia stroke; although neonatal presentation is rare, it can occur ^{201,202} |
| CACT deficiency | 212138 | <i>SLC25A20</i> | AR | Definitive | Dextrose- containing fluids, triheptanoin, restriction of dietary fats, and management of hyperammonemia and cardiac arrhythmias as needed ²⁰³ | Hyperammonemia and cardiac arrhythmia may develop in the first days of life ²⁰³ |
| Carbonic anhydrase VA deficiency | 615751 | <i>CA5A</i> | AR | Definitive | N-carbamyl- glutamate, consideration of protein restriction, dextrose- containing fluids as | Hyperammonemia can develop in the first days of life ²⁰⁴ |

| | | | | | | |
|--|----------------------------|--|----------------|--|--|---|
| | | | | | needed | |
| Citrullinemia type 1 | 215700 | <i>ASS1</i> | AR | Definitive | Low-protein diet, dextrose-containing fluids, and ammonia scavenger medications as needed | Hyperammonemia can develop in the first days of life ²⁰⁵ |
| Classic galactosemia | 230400 | <i>GALT</i> | AR | Definitive | Lactose-restricted diet | Hypoglycemia, liver damage, and E. coli sepsis can develop days after ingesting lactose ²⁰⁶ |
| CPS1 deficiency | 237300 | <i>CPS1</i> | AR | Definitive | Protein restriction, citrulline, sodium benzoate, phenylbutyrate, N-carbamylglutamate | Hyperammonemia can present within the first days of life ²⁰⁷ |
| CPT2 deficiency | 255110 | <i>CPT2</i> | AR | Definitive | Low-fat diet, dextrose-containing fluids, and triheptanoin | Hypoglycemia, liver failure, and cardiomyopathy may develop in the first days of life ²⁰⁸ |
| Dihydrolipoamide dehydrogenase deficiency | 246900 | <i>DLD</i> | AR | Definitive | BCAA-restricted diet, riboflavin, and dextrose-containing fluids | Lactic acidosis and/or liver failure may develop in the first days of life ²⁰⁹ |
| Fructose-1,6-bisphosphatase deficiency | 229700 | <i>FBP1</i> | AR | No VS | Sucrose & fructose restricted diet especially when ill, uncooked cornstarch to limit overnight fasting | More than half of known cases ²¹⁰ present in the first week of life - may be hypoglycemia, lactic acidosis, change in respiratory pattern, hypoglycemia seizure and/or coma. May be lethal in neonatal period if not diagnosed and treated |
| Glutamic-oxaloacetic transaminase 2 deficiency | 618721 | <i>GOT2</i> | AR | No VS | Vitamin B6, serine | Respiratory depression may begin in the first days of life ²¹¹ |
| Glutaric acidemia type II | 231680 231680 231680 | <i>ETFA</i> <i>ETFB</i> <i>ETFDH</i> | AR AR AR | Definitive Definitive Definitive | Low-fat and low-protein diet, dextrose-containing fluids as needed | Hypoglycemia, rhabdomyolysis, cardiac dysfunction, hyperammonemia may develop in the first days of life ²¹² |

| | | | | | | |
|---|------------------|---------------------------|----------|--------------------------|---|---|
| Glycine encephalopathy | 620398 605899 | <i>AMT</i> <i>GLDC</i> | AR AR | Definitive Definitive | Benzoate | Seizures may develop in the first days of life; of note, treatment does not affect long-term development in severe disease, but early diagnosis can help families choose how to direct care ²¹³ |
| Hereditary fructose intolerance | 229600 | <i>ALDOB</i> | AR | No VS | Strict avoidance of fructose | Infant formulas that contain fructo-oligosaccharides, as well as common medications in the neonatal period that contain sucrose (e.g. Sweet-ease) can cause life-threatening hepatic failure in the first week of life ²¹⁴ |
| Hereditary tyrosinemia type 1 | 276700 | <i>FAH</i> | AR | Definitive | Nitisinone | Early treatment can prevent liver failure; individuals treated with nitisinone in the first 30 days of life have no symptoms of tyrosinemia and have no reported hepatocellular carcinoma ²¹⁵ |
| HMG CoA lyase deficiency | 246450 | <i>HMGCL</i> | AR | Definitive | Low-leucine diet, dextrose-containing fluids as needed | Hypoketotic hypoglycemia and hyperammonemia may develop in the first days of life and can cause permanent neurologic injury if not diagnosed and treated ²¹⁶ |
| Holocarboxylase synthetase deficiency | 253270 | <i>HLCS</i> | AR | Definitive | Biotin | Metabolic acidosis may develop in the first days of life ²¹⁷ |
| Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome | 238970 | <i>SLC25A15</i> | AR | Definitive | Protein-restriction, citrulline supplementation, nitrogen scavenger | May present with hyperammonemia in the first week of life ²¹⁸ |
| Hypomagnesemia Type I | 602014 | <i>TRPM6</i> | AR | No VS | Magnesium | Hypomagnesemic seizures can present in the first weeks of |

| | | | | | | |
|--|--|---|----------------------------|--|---|--|
| | | | | | | life, and are refractory without magnesium repletion, ²¹⁹ orthogonal testing is confirmatory and medication is easily available |
| Infantile-onset Pompe disease | 232300 | <i>GAA</i> | AR | Definitive | Infusion of alglucosidase alfa | Symptoms often begin in the prenatal or neonatal period, and improve rapidly with initiation of enzyme replacement therapy ²²⁰ |
| Isolated methylmalonic acidemia | 251000 251100 251110 277410 251120 | <i>MMUT</i> <i>MMAA</i> <i>MMAB</i> <i>MMADHC</i> <i>MCEE</i> | AR AR AR AR AR | Definitive Definitive Definitive Definitive Definitive | B12 (in some genotypes), specialized diet, dextrose-containing fluids and levocarnitine as needed | Metabolic acidosis and hyperammonemia may develop in the first days of life ²¹⁷ |
| Isovaleric acidemia | 243500 | <i>IVD</i> | AR | Definitive | Leucine-free diet, levocarnitine and/or glycine supplementation | Metabolic acidosis may develop in the first hours or days of life ²²¹ |
| Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency | 255100 | <i>FLAD1</i> | AR | Definitive | Riboflavin, carnitine, glycine, Coenzyme Q10 supplementation, fat restriction, avoidance of fasting, carbohydrate-rich diet | Causes a potentially fatal cardiorespiratory insufficiency that may respond to riboflavin ²²² |
| Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and trifunctional protein deficiency | 609016 620300 | <i>HADHA</i> <i>HADHB</i> | AR AR | Definitive Definitive | Low-fat diet, frequent feedings, triheptanoin, dextrose-containing fluids and levocarnitine as needed | Hypoglycemia and cardiomyopathy may develop in the first days of life ²²³ |
| Maple syrup urine disease | 248600 620698 620699 | <i>BCKDHA</i> <i>BCKDHB</i> <i>DBT</i> | AR AR AR | Definitive Definitive Definitive | Leucine-free formula | Elevated leucine may develop in the first hours or days of life and cause cerebral edema ²²⁴ |
| Medium chain acyl-CoA dehydrogenase disorder | 201450 | <i>ACADM</i> | AR | Definitive | Frequent feedings and dextrose-containing fluids as needed | Life-threatening hypoglycemia and/or cardiac arrhythmia may develop in the first days of life ²²⁵ |
| MEDNIK syndrome | 609313 | <i>AP1S1</i> | AR | Definitive | Zinc acetate | GI symptoms, |

| | | | | | | |
|--|------------------|------------------------------|----------|--------------------------|---|---|
| | | | | | | recurrent infections, venous thrombosis and neurologic disease start at birth and early treatment helps those symptoms and may protect against liver failure ²²⁶ |
| Menkes disease | 309400 | <i>ATP7A</i> | XL | Definitive | Subcutaneous copper histidinate | Early treatment enhances survival and improves neuro-development ²²⁷ |
| Mitochondrial complex I deficiency | 611126 | <i>ACAD9</i> | AR | Definitive | Riboflavin, sodium pyruvate, beta-blocker, coenzyme Q10, carnitine | Lactic acidosis and cardiomyopathy may develop in the first days of life ²²⁸ |
| Mitochondrial short chain enoyl-CoA hydratase I deficiency & 3-hydroxyisobutryl-CoA hydrolase deficiency | 616277 250620 | <i>ECHS1</i> <i>HIBCH</i> | AR AR | Definitive Definitive | Valine restricted diet, ketogenic diet | Cardiomyopathy and apnea can develop in the first days of life ²²⁹ |
| Molybdenum cofactor deficiency | 252150 | <i>MOCS1</i> | AR | Definitive | Daily infusions of fosdenopterin ²³⁰ | Seizures may develop in the first days of life; treatment efficacy is dependent on starting in the first 28 days of life ²³¹ |
| MPI-CDG | 602579 | <i>MPI</i> | AR | Definitive | Mannose | Can cause fulminant hepatitis, protein-losing enteropathy and/or coagulopathy in neonatal period ²³² |
| Mucopolysaccharidosis type VI | 253200 | <i>ARSB</i> | AR | Definitive | Galsulfase enzyme replacement | Neonatal initiation of therapy significantly improves long term outcomes ²³³ |
| N-acetylglutamate synthase deficiency | 237310 | <i>NAGS</i> | AR | Definitive | N-carbamyl glutamate, low protein diet, nitrogen scavengers, liver transplant | Hyperammonemia may develop in the first days of life ²³⁴ |
| Ornithine Aminotransferase (OAT) deficiency | 258870 | <i>OAT</i> | AR | Definitive | Low-protein diet and ammonia scavenger medications as needed ²³⁵ | Hyperammonemia may develop in the first days of life ²³⁶ |

| | | | | | | |
|---|--|--|--|---|---|--|
| Ornithine transcarbamylase (OTC) deficiency | 311250 | <i>OTC</i> | XL | Definitive | Low-protein diet, dextrose-containing fluids, and ammonia scavenger medications as needed | Hyperammonemia may develop in the first days of life ²³⁷ |
| PGM1-CDG | 614921 | <i>PGM1</i> | AR | Definitive | Galactose | Neonatal liver dysfunction and hypoglycemia as well as coagulopathy, with studies showing that neonatal treatment improves mortality and long-term outcomes ²³⁸ |
| Primary CoQ10 deficiency | 607426 616276 614654 614652 614651 612016 614650 616733 619028 | <i>COQ2</i> <i>COQ4</i> <i>COQ9</i> <i>PDSS2</i> <i>PDSS1</i> <i>ADCK3</i> <i>COQ6</i> <i>COQ7</i> <i>COQ5</i> | AR AR AR AR AR AR AR AR AR | Definitive Definitive Definitive Moderate No VS No VS No VS No VS No VS | CoQ10 supplementation | Early treatment may prevent infantile encephalopathy, cardiomyopathy and/or renal failure |
| Primary pyruvate dehydrogenase complex deficiency | 312170 245349 245348 614111 608782 | <i>PDHA1</i> <i>PDHX</i> <i>DLAT</i> <i>PDHB</i> <i>PDP1</i> | XL AR AR AR AR | Definitive Definitive Moderate Moderate No VS | Ketogenic diet, thiamine, n-acetylcysteine | Lactic acidosis and seizures may begin in the first days of life ²³⁹ |
| Propionic acidemia | 606054 606054 | <i>PCCA</i> <i>PCCB</i> | AR AR | Definitive Definitive | Specialized diet, dextrose-containing fluids and levocarnitine as needed | Metabolic acidosis and hyperammonemia may begin in the first days of life ²⁴⁰ |
| Pyridoxine-dependent epilepsy | 610090 266100 241500 617290 | <i>PNPO</i> <i>ALDH7A1</i> <i>ALPL</i> <i>PROSC</i> | AR AR AR AR | Definitive Definitive No VS No VS | Pyridoxine ^{110,241} | Immediate treatment may prevent or stop neonatal seizures |
| SLC35A2-CDG | 300896 | <i>SLC35A2</i> | AR | Definitive | D-galactose ²⁴² | Seizures and encephalopathy can develop in the first days of life ²⁴³ |
| Succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency | 245050 | <i>OXCT1</i> | AR | No VS | Dextrose, avoidance of fasting | May present with neonatal ketoacidosis, which may be life threatening ²⁴⁴ |
| Transient infantile liver failure | 613070 | <i>TRMU</i> | AR | Moderate | L-cysteine and N-acetylcysteine | Early treatment may prevent metabolic acidosis and liver |

| | | | | | | |
|---|--|---|--|--|---|---|
| | | | | | | damage; may have neonatal liver failure and/or lactic acidosis ⁶⁹ |
| Very long-chain acyl-CoA dehydrogenase deficiency | 201475 | ACADVL | AR | Definitive | Frequent feedings, low-fat diet, triheptanoin, and dextrose-containing fluids as needed | Hypoglycemia may begin in the first days of life ²⁴⁵ |
| <i>Neurologic disorders</i> | | | | | | |
| Cerebral folate transport deficiency | 613068 | FOLR1 | AR | Definitive | Folinic acid | Presymptomatic folinic acid can reverse symptoms and improve neurologic outcomes ²⁴⁶ |
| Congenital myasthenia syndromes | 614750 610542 615350 614198 618197 616228 617143 616040 601462 616313 616322 608931 616326 254300 616325 613723 603034 616720 615120 254210 617239 616330 618323 616224 | DPAGT1 GFPT1 GMPPB SCN4A SLC25A1 ALG2 SLC5A7 SYT2 CHRNA1 CHRNA1 CHRNB1 CHRND CHRNE RAPSN DOK7 MUSK PLEC COLQ COL13A1 AGRN CHAT SLC18A3 SNAP25 VAMP1 PREPL | AR AR AR AR AR AR AD AD AD AR AR AR AR AR AR AR AR AR AR AR AR AR AD AR AR | Definitive Definitive Definitive Definitive Definitive Strong Moderate Moderate No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS No VS | Dependent on genotype | AChE inhibitors may improve, not change, or worsen respiratory insufficiency depending on genotype ¹¹¹ |
| Early infantile epileptic encephalopathy | 616457 615905 | CAD SLC13A5 | AR AR | Definitive No VS | Uridine ²⁴⁷ Ketogenic diet, stiripentol ²⁴⁸ | Seizures may begin in the first week of life |
| Glucose transporter type 1 deficiency | 606777 | SLC2A1 | AR | Definitive | Ketogenic diet | Diet may prevent onset of seizures ²⁴⁹ |
| m.1555A>G aminoglycoside-induced deafness | 580000 | mtDNA | mtDNA | No VS | Avoidance of aminoglycoside antibiotics | Aminoglycosides are commonly used to prevent neonatal |

| | | | | | | |
|--|--------------------------------------|----------------------------------|----------------------|---|--|--|
| | | | | | | sepsis, but individuals with this variant are at risk for associated hearing loss ^{250,251} |
| Developmental and epileptic encephalopathy | 613721 607745 | SCN2A | AD | Definitive | Sodium channel blocking anti-seizure medications | GOF variants are more responsive to sodium channel blockers; sodium channel blockers should be avoided in LOF variants |
| Self-limited familial neonatal epilepsy, neonatal-onset developmental and epileptic encephalopathy | 121200 617080 605751 121201 | KCNQ2 SCN8A PRRT2 KCNQ3 | AD AD AD AD | Definitive Definitive Definitive No VS | Carbamazepine | Seizures selectively responsive to carbamazepine, KCNQ2 responsive to potassium channel openers (Retigabine and Ezogabine) for LOF variants (not first-line neonatal ASM) ²⁵² ; for SCN8A also better response to sodium-channel blockers |
| STXBP1-related neonatal epilepsy | 612164 | STXBP1 | AD;AR | Definitive | Levetiracetam | Complete seizure control and EEG normalization reported with levetiracetam (not a first-line neonatal ASM) ²⁵³ |
| <i>Renal disorders</i> | | | | | | |
| Cystinosis | 219800 | CTNS | AR | Definitive | Oral cysteamine ^{113,114} | Early treatment may prevent the accumulation of cystine |
| Primary hyperoxaluria type I | 259900 | AGXT | AR | Definitive | Pyridoxine ²⁵⁴ Lumasiran (injection) | Early treatment (effective in some genotypes) may prevent the accumulation of calcium oxalate ¹¹⁵ |
| <i>Pulmonary disorders</i> | | | | | | |
| Surfactant deficiency | 610913 | SFTPC | AD | No VS | Surfactant | Early initiation of surfactant can prevent respiratory distress and |

| | | | | | | |
|--|--|--|--|--|--|------------------------|
| | | | | | | failure ²⁵⁵ |
|--|--|--|--|--|--|------------------------|

Abbreviations: AChE: Acetylcholinesterase; AD: Autosomal dominant; AR: Autosomal recessive; ASM: Anti-seizure medication; BCAA: Branched chain amino acids; DDAVP: Desmopressin; G-CSF: Granulocyte colony stimulating factor; GM-CSF: Granulocyte-macrophage colony-stimulating factor; HSCT: Hematopoietic stem cell transplantation; GOF: Gain of function; 5-HTP: 5-hydroxytryptophan; LT4: Levothyroxine; LOF: Loss of function; MAO-B: Monoamine oxidase B; N/A: Not Applicable due to absent OMIM entry; NSAIDs: Nonsteroidal anti-inflammatory drugs; rhGH: Recombinant human growth hormone; r-hIL-18BP: Recombinant human interleukin-18 binding protein; SCID: Severe combined immunodeficiency; SSRI: Selective serotonin reuptake inhibitors; TSH: Thyroid-stimulating hormone; VS: Validity score; XL: X-linked